Antibodies that bind to the F-protein of metapneumovirus and uses thereof

JP2023552846A5Inactive Publication Date: 2024-11-22HUMABS BIOMED SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023535046
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-11
Filing Date
2021-12-07
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current antibodies against metapneumovirus (MPV) lack sufficient affinity for the prefusion conformation of the F protein, which is crucial for effective neutralization and detection of MPV antigens, and there is a need for improved antibodies to enhance vaccine development against MPV.

Method used

Development of antibodies that specifically bind to the prefusion conformation of the MPV F protein with high affinity, offering enhanced neutralization capabilities and detection of MPV antigens.

Benefits of technology

The developed antibodies effectively neutralize MPV infections and enhance the detection of MPV antigens, providing a stronger immune response and improved vaccine development.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to antibodies and antigen-binding fragments thereof that bind to the F protein (fusion protein) of metapneumovirus (MPV). The antibodies and antigen-binding fragments thereof neutralize MPV infection. The present invention also relates to nucleic acids encoding such antibodies and antigen-binding fragments, and cells expressing such antibodies and antibody fragments. Furthermore, the present invention relates to methods for detecting and testing MPV antigens, and to the use of antibodies and antibody fragments in the diagnosis, treatment, and prevention of MPV infection.
Need to check novelty before this filing date? Find Prior Art

Description

Detailed description of the invention

[0001] The present invention relates to antibodies against metapneumovirus (MPV), particularly antibodies that bind to the metapneumovirus (MPV) F protein (fusion protein) in its pre-fusion conformation. The present invention also relates to the use of such antibodies, for example, in methods for neutralizing MPV infection, methods for detecting MPV antigens, or methods for testing MPV vaccines.

[0002] Human metapneumovirus (hMPV), first isolated in 2001, is a common cause of bronchiolitis and pneumonia in children and the elderly. MPV also causes recurrent infections, including severe lower respiratory tract disease, which can occur at any age, particularly among the elderly or those with impaired heart, lung, or immune systems. MPV is associated with 5%–40% of respiratory infections in hospitalized and outpatient children. Infection with MPV is a significant burden of disease in at-risk premature infants, premature chronic lung disease, congestive heart disease, and immunodeficiency (Martino et al., 2005, Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 11:781-796).

[0003] MPV belongs to the genus Metapneumovirus and family Paramyxoviridae in the subfamily Pneumoviriniae, and is an enveloped, unsegmented minus-strand RNA virus. The genetic structure of MPV is similar to that of respiratory syncytial virus (RSV), but MPV lacks the non-structural genes NS1 and NS2 found in RSV. The envelopes of RSV and MPV contain three transmembrane surface glycoproteins encoded by the virus: major adhesion protein G, fusion protein F, and the low molecular weight hydrophobic SH protein.

[0004] The MPV F protein induces viral penetration by fusion between the virion envelope and the host cell membrane. Initially, the MPV F protein is expressed as a polypeptide precursor ("F0"). The F protein precursor F0 is proteolytically processed at conserved cleavage sites, resulting in the F1 and F2 polypeptides. The mature trimer F protein is formed by the aggregation of three F2-F1 heterodimer protomers and adopts a metastable pre-fusion conformation. The N-terminus of the F subunit is generated by proteolytic cleavage and contains a hydrophobic stretch of amino acids called the fusion peptide, which can be directly inserted into the target membrane to initiate fusion. After binding to the target cell and subsequent activation, the metastable pre-fusion F protein undergoes a series of structural rearrangements, resulting in the fusion of the viral membrane and the target cell membrane and the formation of a stable post-fusion F protein.

[0005] The MPV F protein is a primary target for neutralizing antibodies against MPV and is a target for vaccine development. However, despite the identification of potent neutralizing antibodies such as MPE8 (Corti et al., 2013, Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501: 439-443), the need for antibodies that show increased affinity for the pre-fusion F protein of MPV remains to provide potent MPV neutralization for the detection of the MPV antigen (e.g., in diagnosis) and for the development of vaccines against MPV.

[0006] In view of the above, the object of the present invention is to overcome the shortcomings of the prior art. In particular, the object of the present invention is to provide an antibody that binds to the pre-fusion F protein of MPV with high binding affinity. The object of the present invention is also to provide an antibody that potently neutralizes MPV infection.

[0007] This objective is achieved by the subject matter described below and in the attached claims.

[0008] The present invention is described in detail below, but it should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents described herein, and that these may change. Furthermore, it should be understood that the terms used herein are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art.

[0009] The elements of the present invention are described below. These elements are listed together with specific embodiments, but it should be understood that they can be combined in any manner and in any number to create additional embodiments. The various examples and embodiments described should not be construed as limiting the invention to only the explicitly described embodiments. This description should be understood as supporting and encompassing embodiments combined with the explicitly described embodiments having any number of disclosed elements. Furthermore, any permutations and combinations of all elements described herein should be considered disclosed by this description unless the context suggests otherwise.

[0010] Throughout this specification and the following claims, unless the context requires otherwise, the terms “comprise,” and variations such as “comprises” and “comprising,” are understood to mean the inclusion of specified components, integers, or steps, but not the exclusion of any other unspecified components, integers, or steps. The term “consist of” is a specific embodiment of the term “contains,” and any other unspecified components, integers, or steps are excluded. In the context of the present invention, the term “comprise” encompasses the term “consist of.” Thus, the term “comprising” encompasses “including” and “consisting,” for example, a composition “comprising” X may consist of X alone, or it may include any additional components, such as X + Y.

[0011] In the context describing the present invention (particularly in the context of the claims), the terms “a,” “an,” and “the,” as well as similar references, should be construed to encompass both singular and plural unless otherwise indicated herein or unless the context clearly contradicts this. References of value ranges herein are intended merely as a concise way of individually referring to each individual value that falls within that range. Unless otherwise suggested herein, each individual value is incorporated herein as if it were individually listed herein. No word herein should be construed to indicate an unclaimed element essential to the practice of the present invention.

[0012] The term "substantially" does not exclude "completely"; for example, a composition that "substantially does not contain" Y does not have to contain Y completely. The word "substantially" may be excluded from the definition of this invention as needed.

[0013] The term "approximately" in relation to the number x means x ± 10%, for example, x ± 5%, x ± 7%, x ± 10%, x ± 12%, x ± 15%, or x ± 20%.

[0014] As used herein, the term “disease” is intended to be generally synonymous with and interchangeable with the terms “disorder” and “condition” (as in medical conditions), in that all terms reflect an abnormal condition that impairs the normal function of the human or animal body or one of its parts, typically manifested by distinguishing between signs and symptoms that cause a person or animal to have a reduced duration or quality of life.

[0015] Where used herein, reference to “treatment” of a subject or patient is intended to include prevention, prevention, attenuation, improvement, and treatment. The terms “subject” or “patient” are used interchangeably herein to mean all mammals, including humans. Examples of subjects include humans, cattle, dogs, cats, horses, goats, sheep, pigs, and rabbits. In some embodiments, the patient is human.

[0016] Dosages are often expressed in relation to body weight. Therefore, a dose expressed as [g, mg, or other units] / kg (or g, mg, etc.) usually refers to [g, mg, or other units] "per kg of body weight (or g, mg, etc.)" even if the term "body weight" is not explicitly mentioned.

[0017] The terms "to bond" and similar references usually mean "to bond specifically," and this does not include nonspecific adhesion.

[0018] As used herein, the term “antibody” encompasses a variety of forms of antibodies, including, but not limited to, whole antibodies, antibody fragments (such as antigen-binding fragments), human antibodies, chimeric antibodies, humanized antibodies, recombinant antibodies, and genetically engineered antibodies (mutants or mutant antibodies), as long as they retain the characteristic properties of the present invention. In some embodiments, the antibody is a human antibody. In some embodiments, the antibody is a monoclonal antibody. For example, the antibody is a human monoclonal antibody.

[0019] As stated above, the term “antibody” generally includes antibody fragments. Antibody fragments may retain the antigen-binding activity of an antibody. Such fragments are called “antigen-binding fragments.” Antigen-binding fragments include, but are not limited to, single-chain antibodies, Fab, Fab', F(ab')2, Fv, or scFv. Antibody fragments can be obtained from antibodies by methods including digestion with enzymes such as pepsin or papain, and / or by cleavage of disulfide bonds by chemical reduction. Alternatively, antibody fragments can be obtained by recombinant means, for example, by cloning and expressing a portion (fragment) of the heavy chain and / or light chain sequence. The present invention also includes single-chain Fv fragments (scFv) derived from the heavy and light chains of the antibody of the present invention. For example, the present invention includes scFv containing a CDR derived from the antibody of the present invention. It also includes heavy or light chain monomers and dimers, single-domain heavy chain antibodies, single-domain light chain antibodies, and single-chain antibodies, such as single-chain Fv in which the heavy and light chain variable domains are linked by a peptide linker. The antibody fragments of the present invention may be incorporated into various structures known to those skilled in the art. Furthermore, the sequences of the present invention may be components of a multispecific molecule in which the sequences of the present invention target the epitope of the present invention and other regions of the molecule bind to other targets. This specification, including the claims, may expressly refer to antibody antigen-binding fragments, antibody fragments, variants, and / or derivatives in some places, but the term “antibody” is understood to include all categories of antibodies, namely antibody antigen-binding fragments, antibody fragments, variants, and derivatives.

[0020] Human antibodies are well-known in the latest technologies (van Dijk, MA, and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies may also be produced in transgenic animals (e.g., mice) that can produce a complete repertoire or selection of human antibodies in the absence of endogenous immunoglobulin production during immunization. Transfer of human germline immunoglobulin gene arrays in such germline mutant mice results in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A., et al., Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A., et al., Nature 362 (1993) 255-258; Bruggemann, M., et al., Year Immunol. 7 (1993) 3340). Human antibodies can also be produced in phage display libraries (Hoogenboom, HR, and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, JD, et al., J. Mol. Biol. 222 (1991) 581-597). The techniques of Cole et al. and Boerner et al. are also applicable to the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); and Boerner, P., et al., J. Immunol. 147 (1991) 86-95). In some embodiments, human monoclonal antibodies are prepared using improved EBV-B cell immortalization.Improved EBV-B cell immunization is described in Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. (2004): An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 10(8):871-5. When used herein, "variable region" refers to the variable region (V) of the light chain. L ), variable region of heavy chain (V H The term )) refers to each of the light and heavy chain pairs that are directly involved in the binding of antibodies to an antigen.

[0021] The antibody of the present invention can be any isotype (e.g., IgA, IgG, IgM, i.e., α, γ, or μ heavy chains). For example, the antibody is of the IgG type. Within the IgG isotype, the antibody may be of the IgG1, IgG2, IgG3, or IgG4 subclass, for example, IgG1. The antibody of the present invention may have a κ light chain or a λ light chain. In some embodiments, the antibody is of the IgG1 type and has a κ light chain.

[0022] The antibodies according to the present invention may be provided in a purified form. Typically, the antibodies are present in a composition that is substantially free of other polypeptides, for example, less than 90% (by weight), usually less than 60%, and more usually less than 50% of the composition consists of other polypeptides.

[0023] The antibodies according to the present invention may be immunogenic in human and / or non-human (or heterologous) hosts, such as mice. For example, an antibody may have an idiotope that is immunogenic in a non-human host but not immunogenic in a human host. Antibodies of the present invention for use in humans include those that cannot be readily isolated from hosts such as mice, goats, rabbits, rats, and non-primate mammals, and that cannot generally be obtained from humanized or heterologous mice.

[0024] As used herein, “neutralizing antibody” is an antibody that can neutralize the ability of a pathogen to initiate and / or persist an infection in a host, i.e., it can prevent, inhibit, reduce, impede, or interfere with it. The terms “neutralizing antibody” and “an antibody that neutralizes” or “antibodies that neutralize” are used interchangeably herein. These antibodies can be used alone or in combination as prophylactic or therapeutic agents in appropriate formulations, in association with active vaccine administration, as diagnostic tools, or as production tools as described herein.

[0025] As used herein, the term "mutation" relates to a change in a nucleic acid sequence and / or an amino acid sequence as compared to a reference sequence, e.g., a corresponding genomic sequence. A mutation (e.g., when compared to a genomic sequence) can be, for example, a (naturally occurring) somatic mutation, a spontaneous mutation, an induced mutation, e.g., induced by an enzyme, a chemical or radiation, or a mutation obtained by site-directed mutagenesis (a molecular biological method for creating specific and intentional changes in a nucleic acid sequence and / or an amino acid sequence). Thus, the term "mutation" or "mutating" should be understood to include, for example, physically creating a mutation in a nucleic acid sequence or an amino acid sequence. Mutations include substitutions, deletions and insertions of one or more nucleotides or amino acids, as well as inversions of several consecutive nucleotides or amino acids. To achieve a mutation in an amino acid sequence, a mutation may be introduced into the nucleotide sequence encoding said amino acid sequence in order to express a (recombinant) mutant polypeptide. A mutation may be achieved, for example, by changing the codon of a nucleic acid molecule encoding one amino acid (e.g., by site-directed mutagenesis) to result in a codon encoding a different amino acid, or by synthesizing a sequence variant (e.g., by knowing the nucleotide sequence of a nucleic acid molecule encoding a polypeptide and designing the synthesis of a nucleic acid molecule comprising a nucleotide sequence encoding a variant of the polypeptide without the need to mutate one or more nucleotides of the nucleic acid molecule).

[0026] Several documents are cited throughout this specification. Each document cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.) is hereby incorporated by reference in its entirety, regardless of whether above or below. Nothing in this specification should be construed as an admission that the present invention has no right to antedate such prior disclosure on the basis of prior invention.

[0027] It should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents described herein, which may vary. Also, it should be understood that the terms used herein are for the purpose of describing only particular embodiments and are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0028] (Antibodies and their antigen-binding fragments) In a first aspect, the present invention provides an (isolated) antibody or an antigen-binding fragment thereof that (specifically) binds to the F protein (fusion protein) of metapneumovirus (MPV), particularly human metapneumovirus (hMPV).

[0029] The MPV F protein is a type I transmembrane surface protein having an N-terminal cleavage signal peptide and a membrane anchor near the C-terminus. The MPV F protein assembles to form a homotrimer and is synthesized as an inactive F0 precursor that is activated by cleavage. The F protein is formed by three domains (DI to DIII), a fusion peptide (FP), and three heptad repeat regions (HR-A, -B, and -C). The MPV F glycoprotein induces virus penetration by fusion between the virion envelope and the cell membrane of the host cell. The N-terminus of the F subunit is generated by proteolytic cleavage, contains the fusion peptide, and directly inserts into the target membrane to initiate fusion. After binding to the target cell and subsequent activation, the metastable pre-fusion F protein undergoes a series of structural rearrangements that result in the insertion of the fusion peptide into the target cell membrane, followed by the formation of a stable coiled coil that forms as the virus and cell membranes align. These structural changes result in the formation of a stable post-fusion F protein. After infection, the F protein expressed on the cell surface of infected cells can mediate fusion with adjacent uninfected cells to form large syncytia.

[0030] In some embodiments, the antibody or its antigen-binding fragment binds to the pre-fusion F protein of MPV, particularly human metapneumovirus (hMPV).

[0031] The pre-fusion F protein is the relevant conformation for blocking viral entry. Therefore, antibodies that recognize the pre-fusion conformation of the MPV F protein are particularly effective for neutralization.

[0032] In some embodiments, the binding affinity of the antibody or its antigen-binding fragment is higher for the pre-fusion F protein than for the post-fusion F protein. Therefore, the antibody or its antigen-binding fragment may be selective for the pre-fusion F protein (more so than for the post-fusion F protein). Recognition of abundant post-fusion F proteins, which can act as decoys, consumes the antibody, thereby reducing its effectiveness, which is preferable to reduce or avoid.

[0033] More specifically, 50% antibody binding to the post-fusion F protein of MPV may require an antibody or antigen-binding fragment at least 100 times higher than 50% antibody binding to the pre-fusion F protein of MPV.

[0034] Standard methods for evaluating the binding of the antibody or its antigen-binding fragment according to the present invention are known to those skilled in the art, and include, for example, ELISA (enzyme-linked immunosorbent assay). Thereafter, the relative affinity of antibody binding is determined by the amount of antibody (EC) required to achieve 50% maximum binding when saturated. 50 This can be determined by measuring the concentration of ).

[0035] An exemplary standard ELISA may be performed as follows: An ELISA plate may be coated with a sufficient amount (e.g., 1 μg / ml) of the protein / complex / particle to which antibody binding is to be tested (e.g., MPV F protein in the pre- or post-fusion conformation). The plate may then be incubated with the antibody to be tested. After washing, antibody binding can be elucidated using a labeled antibody that recognizes the test antibody, for example, goat anti-human IgG conjugated to alkaline phosphatase. The plate may then be washed, the required substrate (e.g., p-NPP) added, and the plate read at, for example, 405 nm. The relative affinity of antibody binding is the amount of mAb (EC) required to achieve 50% maximum binding in a saturated state. 50 This can be determined by measuring the concentration of EC. 50 The value may also be calculated by interpolating a combined curve fitted with a 4-parameter nonlinear regression using a variable gradient.

[0036] In some embodiments, the antibody or its antigen-binding fragment neutralizes MPV infection, particularly hMPV infection. The antibody and antigen-binding fragment of the present invention may have high neutralizing capacity. The concentration of the antibody of the present invention required for 50% neutralization of MPV is, for example, about 500 ng / ml or less. In certain embodiments, the concentration of the antibody of the present invention required for 50% neutralization of MPV is about 500, 450, 400, 350, 300, 250, 200, 175, 150, 125, or about 100 ng / ml or less. This means that only low concentrations of antibody are required for 50% neutralization of MPV. Specificity and capacity can be measured using standard assays known to those skilled in the art.

[0037] Those skilled in the art are familiar with various standard "neutralization assays," for example, for studying and quantifying neutralization in the laboratory. For a neutralization assay, the virus (to be neutralized) is typically grown in cells and / or cell lines. For example, in a neutralization assay, cultured cells may be incubated with a certain amount of MPV (hMPV) in the presence (or absence) of the antibody being tested. Flow cytometry, for example, can be used as a readout. Alternatively, other readouts may be considered.

[0038] In some embodiments, the antibody or its antigen-binding fragment specifically binds to the F protein of MPV subgroups A1, A2, B1, and B2, i.e., to all four subgroups of MPV. Therefore, the antibody or its antigen-binding fragment may neutralize infection to MPV subgroups A1, A2, B1, and B2, i.e., all four subgroups of MPV. The amino acid sequences of the G and F proteins of MPV are classified into groups A and B, and further divided into four subgroups: A1, A2, B1, and B2. As shown in the attached examples, the antibody or antigen-binding fragment of the present invention specifically binds to all four subgroups of MPV: A1, A2, B1, and B2. Furthermore, in some embodiments, the antibody or antigen-binding fragment of the present invention potently neutralizes all four subgroups of MPV: A1, A2, B1, and B2.

[0039] In some embodiments, the antibody or its antigen-binding fragment binds to the same (or overlapping) epitope as MPE8 (see, for example, Corti et al., 2013, Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501: 439-443 (which is incorporated herein by reference)). MPE8 has been described as binding to an epitope near the central section of the RSV (and possibly MPV) F extradomain at the intersection of the DI, DII, and DIII domains derived from two subunits of the F trimer (also called "antigen site III").

[0040] In other embodiments, the antibody or its antigen-binding fragment binds to an epitope on the MPV F protein that is different from (and does not overlap with) the MPE8 epitope (i.e., different from antigen site III).

[0041] Generally, an antibody or its antigen-binding fragment according to the present invention may contain (at least) three complementarity-determining regions (CDRs) on the heavy chain and (at least) three CDRs on the light chain. Generally, complementarity-determining regions (CDRs) are hypervariable regions present in the heavy chain variable domain and the light chain variable domain. Typically, the CDRs of the antibody's heavy chain and the linked light chain come together to form an antigen receptor. Usually, the three CDRs (CDR1, CDR2, and CDR3) are arranged discontinuously in the variable domain. Since an antigen receptor typically consists of two variable domains (two different polypeptide chains, i.e., the heavy chain and the light chain: on the heavy chain variable region (VH) and the light chain variable region (VL)), there are typically six CDRs for each antigen receptor (heavy chain: CDRH1, CDRH2, and CDRH3; light chain: CDRL1, CDRL2, and CDRL3). For example, a classical IgG antibody molecule usually has two antigen receptors and therefore contains 12 CDRs. CDRs on the heavy and / or light chains may be separated by framework regions, thereby the framework regions (FRs) being regions within the variable domain that are less "variable" than the CDRs. For example, a variable region (or each variable region) may consist of four framework regions separated by three CDRs.

[0042] The heavy and light chain sequences of an exemplary antibody of the present invention, containing three different CDRs on the heavy chain and three different CDRs on the light chain, were determined. The positions of the CDR amino acids are defined by the IMGT numbering system (IMGT: http: / / www.imgt.org / ; cf. Lefranc, M.-P. et al. (2009) Nucleic Acids Res. 37, D1006-D1012).

[0043] In some embodiments, the antibody or its antigen-binding fragment is (i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, respectively. (iii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 18, respectively; or (iv) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.

[0044] In some embodiments, the antibody or its antigen-binding fragment is (i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, respectively. (iii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 18, respectively; or (iv) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.

[0045] As used herein, “sequence identity” is typically calculated with respect to the entire length of the reference sequence (i.e., the sequence described in this application). Percentage identity as referred herein can be determined by methods known in the art, such as blasting, using default parameters specified by NCBI (the National Center for Biotechnology Information; http: / / www.ncbi.nlm.nih.gov / ) [Blosum 62 matrix; gap open penalty=11 and gap extension penalty=1].

[0046] A "sequence variant" has an altered sequence in which one or more amino acids in the reference sequence are deleted or substituted, and / or one or more amino acids are inserted into the sequence of the reference amino acid sequence. As a result of the alteration, the amino acid sequence variant has an amino acid sequence that is at least 70% identical to the reference sequence. The variant sequence that is at least 70% identical has 30 or fewer alterations per 100 amino acids of the reference sequence, i.e., any combination of deletions, insertions, or substitutions. In the "sequence variant," the functionality of the reference sequence (for example, binding to the F protein of MPV in this case) may be maintained.

[0047] Generally, non-conservative amino acid substitutions are possible, but substitutions are usually conserved amino acid substitutions, where the substituted amino acid has similar structural or chemical properties to the corresponding amino acid in the reference sequence. Examples of conservative amino acid substitutions include the substitution of one aliphatic or hydrophobic amino acid, e.g., alanine, valine, leucine, and isoleucine, with another amino acid; the substitution of one hydroxyl-containing amino acid, e.g., serine and threonine, with another amino acid; the substitution of one acidic residue, e.g., glutamic acid or aspartic acid, with another amino acid; the substitution of one amide-containing residue, e.g., asparagine and glutamine, with another amino acid; the substitution of one aromatic residue, e.g., phenylalanine and tyrosine, with another amino acid; the substitution of one basic residue, e.g., lysine, arginine, and histidine, with another amino acid; and the substitution of one small amino acid, e.g., alanine, serine, threonine, cysteine, and glycine, with another amino acid.

[0048] Amino acid insertions include amino and / or carboxyl terminal fusions ranging in length from one residue to polypeptides containing 100 or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include the fusion of amino acid sequences to the N-terminus or C-terminus of a reporter molecule or enzyme.

[0049] The antibody or antigen-binding fragment of the present invention (i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and at least 90% (e.g., 91%) sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 7, respectively. (ii) Light chain CDR1, CDR2, and CDR3 sequences having sequence identity of at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) of the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively; or (ii) Heavy chain CDR1, CDR2, and CDR3 sequences having sequence identity of at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more); (iii) Light chain CDR1, CDR2, and CDR3 sequences having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) sequence identity with the DR3 sequence, and the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, respectively; or (iii) at least 90% (e.g., 91%, 92%, Heavy chain CDR1, CDR2, and CDR3 sequences having sequence identity of 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more, and light chain CDR1, CDR2, and CDR3 sequences having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 18, respectively;Or (iv) it may include heavy chain CDR1, CDR2, and CDR3 sequences having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.

[0050] In some embodiments, the antibody or its antigen-binding fragment is: - A heavy chain CDR1 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1; - A heavy chain CDR2 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 2; - A heavy chain CDR3 sequence having at least 85% or 90% sequence identity with the amino acid sequence of SEQ ID NO: 3; - A light chain CDR1 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 4; - A light chain CDR2 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 5 or 6; and -Includes a light chain CDR3 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 7.

[0051] More specifically, an antibody or its antigen-binding fragment is: - Heavy chain CDR1 sequence as described in Sequence ID No. 1; - Heavy chain CDR2 sequence described in Sequence ID No. 2; - A heavy chain CDR3 sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 3; -Light chain CDR1 sequence as described in Sequence ID No. 4; -Light chain CDR2 sequences described in Sequence ID No. 5 or 6; and -May include the light chain CDR3 sequence described in Sequence ID No. 7.

[0052] In some embodiments, the C-terminal Asp(D) residue of SEQ ID NO: 3 is substituted. More specifically, the C-terminal Asp residue of SEQ ID NO: 3 may be substituted with another polar amino acid. Examples of polar amino acids include arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, threonine, and tyrosine. For example, the C-terminal aspartic acid residue of SEQ ID NO: 3 may be substituted with a histidine residue. Thus, the antibody or its antigen-binding fragment may contain a heavy chain CDR3 sequence according to SEQ ID NO: 3 or 10.

[0053] Therefore, the antibody or its antigen-binding fragment is: - Heavy chain CDR1 sequence as described in Sequence ID No. 1; - Heavy chain CDR2 sequence described in Sequence ID No. 2; - Heavy chain CDR3 sequence described in Sequence ID No. 3; -Light chain CDR1 sequence as described in Sequence ID No. 4; -Light chain CDR2 sequences described in Sequence ID No. 5 or 6; and -May include the light chain CDR3 sequence described in Sequence ID No. 7.

[0054] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence as described in Sequence ID No. 1; - Heavy chain CDR2 sequence described in Sequence ID No. 2; - Heavy chain CDR3 sequence described in Sequence ID No. 10; -Light chain CDR1 sequence as described in Sequence ID No. 4; -Light chain CDR2 sequences described in Sequence ID No. 5 or 6; and -May include the light chain CDR3 sequence described in Sequence ID No. 7.

[0055] In other embodiments, the antibody or its antigen-binding fragment is: - A heavy chain CDR1 sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 12; - A heavy chain CDR2 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 13; - A heavy chain CDR3 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 14; - A light chain CDR1 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 15; - A light chain CDR2 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 16 or 17; and -May also include a light chain CDR3 sequence having at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 18.

[0056] More specifically, an antibody or its antigen-binding fragment is: - A heavy chain CDR1 sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 12; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence according to SEQ ID NO: 18.

[0057] In some embodiments, one or more amino acid residues N34, S36, and C38 of the heavy chain variable region (corresponding to N6, S8, and C10 of SEQ ID NO: 12, respectively) are substituted. More specifically, -N34 (corresponding to N6 in SEQ ID NO: 12) may be substituted with another polar amino acid such as Gln(Q) or Ser(S); -S36 (corresponding to S8 in SEQ ID NO: 12) may be substituted with another small amino acid such as Ala(A); and / or -C38 (corresponding to C10 in SEQ ID NO: 12) may be substituted with any amino acid such as Ser(S), Ala(A), or Tyr(Y).

[0058] Examples of polar amino acids include arginine, asparagine, aspartic acid, glutamine, glutamic acid, histidine, lysine, serine, threonine, and tyrosine. Examples of small amino acids include alanine, serine, threonine, glycine, cysteine, proline, asparagine, and aspartic acid, with alanine, glycine, and serine being particularly small.

[0059] The heavy chain CDR1 sequence, antibody, or antigen-binding fragment may differ from SEQ ID NO: 12 by up to three amino acids, particularly as described above. In some embodiments, the heavy chain CDR1 sequence, antibody, or antigen-binding fragment may differ from SEQ ID NO: 12 by a single amino acid substitution, selected from N34, S36, and C38, as described above. In other embodiments, the heavy chain CDR1 sequence, antibody, or antigen-binding fragment differs from SEQ ID NO: 12 in that it has (exactly) two amino acid substitutions, which may be selected from N34 / S36, N34 / C38, and S36 / C38, for example, the amino acid residue of N34 / C38 may be substituted as described above.

[0060] For example, the antibody or its antigen-binding fragment may contain a heavy chain CDR1 sequence as described in any one of SEQ ID NOs: 12, 21, 23, 25, 27, 29, 31, and 33.

[0061] Therefore, the antibody or its antigen-binding fragment is: - Heavy chain CDR1 sequence as described in Sequence ID No. 12; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0062] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence as described in Sequence ID No. 21; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0063] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence as described in Sequence ID No. 23; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0064] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence described in Sequence ID No. 25; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0065] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence described in Sequence ID No. 27; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0066] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence as described in Sequence ID No. 29; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence according to SEQ ID NO: 18.

[0067] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence as described in Sequence ID No. 31; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0068] Alternatively, the antibody or its antigen-binding fragment may be: - Heavy chain CDR1 sequence as described in Sequence ID No. 33; - Heavy chain CDR2 sequence described in Sequence ID No. 13; - Heavy chain CDR3 sequence described in Sequence ID No. 14; -Light chain CDR1 sequence described in Sequence ID No. 15; - Light chain CDR2 sequences described in Sequence ID No. 16 or 17; and -May include the light chain CDR3 sequence described in Sequence ID No. 18.

[0069] In some embodiments, the antibody or antigen-binding fragment of the present invention has (i) an amino acid sequence having 70% or more identity with SEQ ID NO: 8 (e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). It includes a heavy chain variable region (VH) containing and a light chain variable region (VL) containing an amino acid sequence having identity with SEQ ID NO: 9 by 70% or more (e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). Thereafter, the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or 10, respectively; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 4, SEQ ID NO: 5 or 6, and SEQ ID NO: 7, respectively) may be maintained.

[0070] In some embodiments, the antibody or antigen-binding fragment of the present invention has (i) an amino acid having identity of 70% or more (e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) with SEQ ID NO: 19. It includes a heavy chain variable region containing an acid sequence, and a light chain variable region containing an amino acid sequence having 70% or more identity with SEQ ID NO: 20 (e.g., 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). This may maintain the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NOs. 12, 21, 23, 25, 27, 29, 31, or 33; SEQ ID NOs. 13; and SEQ ID NOs. 14, respectively; as well as the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NOs. 15, SEQ ID NOs. 16 or 17, and SEQ ID NOs. 20, respectively).

[0071] In some embodiments, the antibody or antigen-binding fragment of the present invention has (i) an amino acid having identity with SEQ ID NO: 8 by 75% or more (e.g., 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). It includes a heavy chain variable region containing an acid sequence, and a light chain variable region containing an amino acid sequence having 75% or more identity with SEQ ID NO: 9 (e.g., 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). Thereafter, the CDR sequences defined above (heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or 10, respectively; and light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 4, SEQ ID NO: 5 or 6, and SEQ ID NO: 7, respectively) may be maintained.

[0072] In some embodiments, the antibody or antigen-binding fragment of the present invention has (i) an amino acid having 75% or more identity with SEQ ID NO: 19 (e.g., 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). It includes a heavy chain variable region containing an acid sequence, and a light chain variable region containing an amino acid sequence having 75% or more identity with SEQ ID NO: 20 (e.g., 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). Thereafter, the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 12, 21, 23, 25, 27, 29, 31, or 33; SEQ ID NO: 13; and SEQ ID NO: 14, respectively; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 15, SEQ ID NO: 16, or 17, and SEQ ID NO: 20, respectively) may be maintained.

[0073] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 80% or more identity with SEQ ID NO: 8 (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more), and a light chain variable region comprising an amino acid sequence having 80% or more identity with SEQ ID NO: 9 (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). This may maintain the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or 10, respectively; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 4, SEQ ID NO: 5 or 6, and SEQ ID NO: 7, respectively).

[0074] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 80% or more identity with SEQ ID NO: 19 (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more), and a light chain variable region comprising an amino acid sequence having 80% or more identity with SEQ ID NO: 20 (e.g., 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). This may maintain the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NOs. 12, 21, 23, 25, 27, 29, 31, or 33; SEQ ID NOs. 13; and SEQ ID NOs. 14, respectively; as well as the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NOs. 15, SEQ ID NOs. 16 or 17, and SEQ ID NOs. 20, respectively).

[0075] In some embodiments, the antibody of the present invention or its antigen-binding fragment includes (i) a heavy chain variable region comprising an amino acid sequence having 85% or more identity with SEQ ID NO: 8 (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more), and a light chain variable region comprising an amino acid sequence having 85% or more identity with SEQ ID NO: 9 (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). This may maintain the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or 10, respectively; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 4, SEQ ID NO: 5 or 6, and SEQ ID NO: 7, respectively).

[0076] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 85% or more identity with SEQ ID NO: 19 (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more), and a light chain variable region comprising an amino acid sequence having 85% or more identity with SEQ ID NO: 20 (e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more). This may maintain the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NOs. 12, 21, 23, 25, 27, 29, 31, or 33; SEQ ID NOs. 13; and SEQ ID NOs. 14, respectively; as well as the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NOs. 15, SEQ ID NOs. 16 or 17, and SEQ ID NOs. 20, respectively).

[0077] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 90% or more identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 8, and a light chain variable region comprising an amino acid sequence having 90% or more identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 9. Thereafter, the CDR sequences defined above (heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or 10, respectively; and light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 4, SEQ ID NO: 5 or 6, and SEQ ID NO: 7, respectively) may be maintained.

[0078] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 90% or more identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 19, and a light chain variable region comprising an amino acid sequence having 90% or more identity (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 20. Thereafter, the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 12, 21, 23, 25, 27, 29, 31, or 33; SEQ ID NO: 13; and SEQ ID NO: 14; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 15, SEQ ID NO: 16, or 17; and SEQ ID NO: 20, respectively) may be maintained.

[0079] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 95% or more identity (e.g., 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 8, and a light chain variable region comprising an amino acid sequence having 95% or more identity (e.g., 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 9. Thereafter, the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or 10, respectively; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 4, SEQ ID NO: 5 or 6, and SEQ ID NO: 7, respectively) may be maintained.

[0080] In some embodiments, the antibody or antigen-binding fragment of the present invention includes (i) a heavy chain variable region comprising an amino acid sequence having 95% or more identity (e.g., 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 19, and a light chain variable region comprising an amino acid sequence having 95% or more identity (e.g., 96%, 97%, 98%, 99%, or more) with SEQ ID NO: 20. Thereafter, the CDR sequences defined above (the heavy chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 12, 21, 23, 25, 27, 29, 31, or 33; SEQ ID NO: 13; and SEQ ID NO: 14; and the light chain CDR1, CDR2, and CDR3 sequences described in SEQ ID NO: 15, SEQ ID NO: 16, or 17; and SEQ ID NO: 20, respectively) may be maintained.

[0081] More specifically, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 8, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 9.

[0082] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 11 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 9.

[0083] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 19 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0084] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 22 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0085] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 24 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0086] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 26 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0087] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 28 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0088] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 30 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0089] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 32 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0090] Alternatively, the antibody or its antigen-binding fragment may include a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 34 and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 20.

[0091] Table 1 below shows the CDR and VH / VL sequences of exemplary antibodies of the present invention, namely antibodies MPF5_VH117D(MPF5) and MPF5_VH117H, MPE33, MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, and MPE33_N34S_C38Y.

[0092] [Table 1]

[0093] In some embodiments, the antibody of the present invention is a human antibody. In some embodiments, the antibody of the present invention is a monoclonal antibody. For example, the antibody of the present invention may be a human monoclonal antibody.

[0094] The antibody of the present invention may be of any isotype (e.g., IgA, IgG, IgM, i.e., α, γ, or μ heavy chains). For example, the antibody may be of the IgG type. Within the range of IgG isotypes, the antibody may be of the IgG1, IgG2, IgG3, or IgG4 subclass, for example, IgG1. The antibody of the present invention may have a κ light chain or a λ light chain. In some embodiments, the antibody is of the IgG1 type and has a lambda light chain or a kappa light chain.

[0095] In some embodiments, the antibody is of human IgG1 type. The antibody may be any allotype. The term “allotype” refers to an allele mutation found among IgG subclasses. For example, the antibody may be a G1m1 (or G1m(a)) allotype, a G1m2 (or G1m(x)) allotype, a G1m3 (or G1m(f)) allotype, and / or a G1m17 (or Gm(z)) allotype. The G1m3 and G1m17 allotypes are located at the same position in the CH1 domain (position 214 according to EU numbering). G1m3 corresponds to R214(EU), while G1m17 corresponds to K214(EU). The G1m1 allotype is located in the CH3 domain (positions 356 and 358(EU)) and refers to substitutions E356D and M358L. The G1m2 allotype refers to the substitution of alanine at position 431 (EU) with glycine. The G1m1 allotype can be combined with, for example, the G1m3 or G1m17 allotype. In some embodiments, the antibody is of allotype G1m3 (G1m3,-1) which does not have G1m1. In some embodiments, the antibody is of allotype G1m17,1. In some embodiments, the antibody is of allotype G1m3,1. In some embodiments, the antibody is of allotype G1m17 (G1m17,-1) which does not have G1m1. Optionally, these allotypes may be combined with (or not combined with) the G1m2, G1m27, or G1m28 allotypes. For example, the antibody may be of allotype G1m17,1,2.

[0096] In some embodiments, the antibody or antigen-binding fragment according to the present invention includes an Fc moiety. The Fc moiety may be of human origin, for example, human IgG1, IgG2, IgG3, and / or IgG4, for example, human IgG1.

[0097] As used herein, the term “Fc moiety” refers to a sequence derived from a portion of an immunoglobulin heavy chain. This immunoglobulin heavy chain begins at a hinge region immediately upstream of the papain cleavage site (e.g., residue 216 in native IgG, with the first residue of the heavy chain constant region being 114) and ends at the C-terminus of the immunoglobulin heavy chain. Therefore, the Fc moiety may be a complete Fc moiety or a portion thereof (e.g., a domain). A complete Fc moiety includes at least a hinge domain, a CH2 domain, and a CH3 domain (e.g., EU amino acid positions 216–446). Additional lysine residues (K) may be present at the extreme C-terminus of the Fc moiety but are often cleaved by mature antibodies.

[0098] Each amino acid position within the Fc portion is numbered herein according to the Kabat EU numbering system recognized in the art (for example, Kabat et al., in “Sequences of Proteins of Immunological Interest”, US Dept. Health and Human Services, 1983 and 1987; see these for details). The EU index, or EU index such as Kabat, or EU numbering refers to the numbering of EU antibodies (Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gammaG immunoglobulin molecule. Proc Natl Acad Sci US A. 1969;63(1):78-85; Kabat EA, National Institutes of Health (US) Office of the Director, “Sequences of Proteins of Immunological Interest”, 5th edition, Bethesda, MD: US Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 199, is incorporated into this application by reference in its entirety.) In some embodiments, within the context of the present invention, the Fc portion comprises at least one of the hinge domains (e.g., upper, central, and / or lower hinge regions), CH2 domains, CH3 domains, or variants, portions, or fragments thereof. The Fc portion may comprise at least a hinge domain, a CH2 domain, or a CH3 domain. The Fc portion may also comprise a complete Fc portion. The Fc portion may also comprise one or more amino acid insertions, deletions, or substitutions compared to naturally occurring Fc portions. For example, at least one of the hinge domains, CH2 domains, or CH3 domains (or portions thereof) may be deleted. For example, the Fc portion may include or consist of (i) a hinge domain (or a portion thereof) fused to a CH2 domain (or a portion thereof), (ii) a hinge domain (or a portion thereof) fused to a CH3 domain (or a portion thereof), (iii) a CH2 domain (or a portion thereof) fused to a CH3 domain (or a portion thereof), (iv) a hinge domain (or a portion thereof), (v) a CH2 domain (or a portion thereof), or (vi) a CH3 domain or a portion thereof.

[0099] The Fc moiety may be modified so as to alter the amino acid sequence from the complete Fc moiety of a naturally occurring immunoglobulin molecule, while retaining at least one desirable function conferred by the naturally occurring Fc moiety, as will be understood by those skilled in the art. Such functions include Fc receptor (FcR) binding, antibody half-life regulation, ADCC function, protein A binding, protein G binding, and complement binding. The portions of the naturally occurring Fc moiety that are involved in and / or essential for such functions are well known to those skilled in the art.

[0100] For example, to activate complement cascade C1q binding to at least two molecules of IgG1 or one molecule of IgM attached to an antigen target (Ward, ES, and Ghetie, V., Ther. Immunol. 2 (1995) 77-94). Burton, DR (Mol. Immunol. 22 (1985) 161-206) describes that the heavy chain region containing amino acid residues 318-337 is involved in complement fixation. Duncan, AR, and Winter, G. (Nature 332 (1988) 738-740) reported, using site-directed mutagenesis, that Glu318, Lys320, and Lys322 form the binding site to C1q. The roles of the Glu318, Lys320, and Lys322 residues in C1q binding were confirmed by the ability of short synthetic peptides containing these residues to inhibit complement-mediated lysis.

[0101] For example, FcR binding can be mediated by the interaction between the Fc portion (of an antibody) and the Fc receptor (FcR), a specialized cell surface receptor on hematopoietic cells. Fc receptors belong to the immunoglobulin superfamily and have been shown to mediate both the removal of antibody-coated pathogens by phagocytosis of immune complexes and the lysis of red blood cells and various other cell targets (e.g., tumor cells) coated with the corresponding antibody via antibody-dependent cell-mediated cytotoxicity (ADCC; Van de Winkel, JG, and Anderson, CL, J. Leukoc. Biol. 49 (1991) 511-524). FcRs are defined by their specificity for immunoglobulin classes; the Fc receptor for IgG antibodies is called FcγR, for IgE it is called FcεR, for IgA it is called FcαR, and so on, while the neonatal Fc receptor is called FcRn. Fc receptor binding is described, for example, in Ravetch, JV, and Kinet, JP, Annu. Rev. Immunol. 9 (1991) 457-492; Capel, PJ, et al., Immunomethods 4 (1994) 25-34; de Haas, M., et al., J Lab. Clin. Med. 126 (1995) 330-341; and Gessner, JE, et al., Ann. Hematol. 76 (1998) 231-248.

[0102] Receptor crosslinking by the Fc domain of native IgG antibodies (FcγRs) induces a wide variety of effector functions, including phagocytosis, antibody-dependent cell-mediated cytotoxicity, release of inflammatory mediators, and regulation of immune complex clearance and antibody production. Therefore, the Fc moiety may provide crosslinking of the receptor (FcγR). In humans, three classes of FcγRs have been characterized. (i) FcγRI(CD64), which binds to monomeric IgG with high affinity and is expressed on macrophages, monocytes, neutrophils, and eosinophils; (ii) FcγRII(CD32), which binds to complexed IgG with low affinity and is widely expressed, but is particularly expressed on leukocytes, which are known to play a central role in antibody-mediated immunity, and is known to be divided into FcγRIIA, FcγRIIB, and FcγRIIC, which perform different functions in the immune system but bind with low affinity similar to IgG-Fc, and the external domains of these receptors have high homology; (iii) FcγRIIII(CD16), which binds to IgG with medium to low affinity and exists as two types (FcγRIIA, which is found on NK cells, macrophages, eosinophils, and some monocytes, and T cells and mediates ADCC, and FcγRIIB, which is highly expressed on neutrophils). FcγRIIA is found in many cells involved in killing (e.g., macrophages, monocytes, neutrophils) and appears to be capable of activating the killing process. FcγRIIB appears to play a role in the inhibitory process and is found on B cells, macrophages, mast cells, and eosinophils. Importantly, 75% of all FcγRIIBs are found in the liver (Ganesan, LP et al., 2012: FcγRIIb on liver sinusoidal endothelium clears small immune complexes. Journal of Immunology 189: 4981-4988).FcγRIIB is abundantly expressed on liver sinusoidal endothelium (LSEC), and Kupffer cells in the liver and LSEC are major sites for small immune complex clearance (Ganesan, LP et al., 2012: FcγRIIb on liver sinusoidal endothelium clears small immune complexes. Journal of Immunology 189: 4981-4988).

[0103] Therefore, the antibody and its antigen-binding fragment of the present invention may be bound to FcγRIIb, for example, an antibody containing an Fc moiety for binding to FcγRIIb, particularly an Fc region such as an IgG-type antibody. Furthermore, as described in Chu, SY et al., 2008: Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Molecular Immunology 45, 3926-3933, the Fc moiety can be designed to enhance FcγRIIB binding by introducing mutations in S267E and L328F. This can enhance the clearance of immune complexes (Chu, S., et al., 2014: Accelerated Clearance of IgE In Chimpanzees Is Mediated By Xmab7195, An Fc-Engineered Antibody With Enhanced Affinity For Inhibitory Receptor FcγRIIb. Am J Respir Crit, American Thoracic Society International Conference Abstracts). Therefore, the antibody or antigen-binding fragment of the present invention may contain a designed Fc moiety having the S267E and L328F mutations, as described in Chu, SY et al., 2008: Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Molecular Immunology 45, 3926-3933.

[0104] On B cells, it appears to function by suppressing further immunoglobulin production and isotype switching, for example, by acting as an IgE class. On macrophages, FcγRIIB acts to inhibit phagocytosis mediated via FcγRIIA. On eosinophils and mast cells, type b (b form) may help suppress the activation of these cells through IgE binding to its distinct receptors.

[0105] Regarding FcγRI binding, modifications in at least one of the following natural IgG residues—E233-G236, P238, D265, N297, A327, and P329—reduce FcγRI binding. IgG2 residues at positions 233-236, substituted with IgG1 and IgG4, reduce FcγRI binding by 10. 3This was reduced by a factor of 2, eliminating the human monocyte response to antibody-sensitized erythrocytes (Armour, KL, et al. Eur. J. Immunol. 29 (1999) 2613-2624). Regarding FcγRII binding, decreased binding to FcγRII was observed for at least one IgG mutation, for example, E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, R292, and K414. Regarding FcγRIII binding, decreased binding to FcγRIIIA is observed for at least one mutation in, for example, E233-G236, P238, D265, N297, A327, P329, D270, Q295, A327, S239, E269, E293, Y296, V303, A327, K338, and D376. Mapping of binding sites on human IgG1 for the Fc receptor, the above mutation sites and methods for measuring binding to FcγRI and FcγRIIA are described in Shields, RL, et al., J. Biol. Chem. 276 (2001) 6591-6604. For example, single (S239D or I332E), double (S239D / I332E), and triple (S239D / I332E / A330L) mutations improved affinity for human FcγRIIIa. Furthermore, the addition of the S239D / I332E mutation to G236A not only improved the FcγRIIa:FcγRIIb ratio but also enhanced binding to FcγRIIIa. Thus, it has been described that the G236A / S239D / A330L / I332E mutation enhances engagement with FcγRIIa and FcγRIIIa.

[0106] Regarding the crucial binding to FcγRII, two regions of native IgG Fc, namely (i) the lower hinge region of IgG Fc, particularly amino acid residues L, L, G, G (234-237, EU numbering), and (ii) the region adjacent to the CH2 domain of IgG Fc, particularly the loop and strand of the upper CH2 domain adjacent to the lower hinge region, e.g., the P331 region (Wines, BD, et al., J. Immunol. 2000; 164: 5313 - 5318), appear to be important for the interaction between FcγRII and IgG. Furthermore, while FcγRII appears to bind to the same site on IgG Fc, FcRn and protein A bind to different sites on IgG Fc, which appear to be at the CH2-CH3 interface (Wines, BD, et al., J. Immunol. 2000; 164: 5313 - 5318).

[0107] For example, the Fc portion may include, or be composed of, at least a portion of an Fc portion known in the art to be required for FcRn binding or an extended half-life. Alternatively, or in addition, the Fc portion of the antibody of the present invention may include at least a portion known in the art to be required for protein A binding, and / or the Fc portion of the antibody of the present invention may include at least a portion of an Fc molecule known in the art to be required for protein G binding. The Fc portion may also include at least a portion known in the art to be required for FcγR binding. Therefore, as outlined above, the Fc portion may include (i) the lower hinge region of the natural IgG Fc, particularly amino acid residues L, L, G, G (234-237, EU numbering), and (ii) the adjacent region of the CH2 domain of the natural IgG Fc, particularly the loops and strands in the upper CH2 domain adjacent to the lower hinge region (e.g., in the P331 region), for example, a region of at least 3, 4, 5, 6, 7, 8, 9, or 10 consecutive amino acid regions in the upper CH2 domain around P331 of the natural IgG Fc (e.g., between amino acids 320 and 340 of the natural IgG Fc (EU numbering)).

[0108] In some embodiments, the antibody or antigen-binding fragment according to the present invention includes an Fc region. As used herein, the term “Fc region” refers to a portion of an immunoglobulin formed by two or more Fc parietes of an antibody heavy chain. For example, an Fc region may be a monomeric Fc region or a “single-chain” Fc region (i.e., an scFc region). A single-chain Fc region consists of Fc parietes linked within a single polypeptide chain (e.g., encoded in a single consecutive nucleic acid sequence). An exemplary scFc region is disclosed in WO2008 / 143954A2. An Fc region may be a dimer. “Dimer Fc region” or “dcFc” refers to a dimer formed by Fc parietes of two separate immunoglobulin heavy chains. A dimer Fc region may be a homodimer of two identical Fc parietes (e.g., Fc regions of naturally occurring immunoglobulins) or a heterodimer of two non-identical Fc parietes.

[0109] The Fc portions of an Fc region may be of the same or different classes and / or subclasses. For example, the Fc portions may originate from immunoglobulins of the IgG1, IgG2, IgG3, or IgG4 subclass (e.g., human immunoglobulins). The Fc portions of an Fc region may be of the same class and subclass. However, an Fc region (or one or more Fc portions of an Fc region) may be chimeric, and a chimeric Fc region may contain Fc portions derived from different immunoglobulin classes and / or subclasses. For example, at least two Fc portions of a dimer or single-stranded Fc region may originate from different immunoglobulin classes and / or subclasses. Alternatively, or in addition, a chimeric Fc region may contain one or more chimeric Fc portions. For example, a chimeric Fc region or portion may contain one or more portions derived from an immunoglobulin of a first subclass (e.g., IgG1, IgG2, or IgG3 subclass), and the remainder of the Fc region or portion may be from different subclasses. For example, the Fc region or portion of an Fc polypeptide may include a CH2 and / or CH3 domain derived from an immunoglobulin of a first subclass (e.g., IgG1, IgG2, or IgG4 subclass) and a hinge region derived from an immunoglobulin of a second subclass (e.g., IgG3 subclass). For example, the Fc region or portion may include a hinge and / or CH2 domain derived from an immunoglobulin of a first subclass (e.g., IgG4 subclass) and a CH3 domain derived from an immunoglobulin of a second subclass (e.g., IgG1, IgG2, or IgG3 subclass). For example, a chimeric Fc region may include an Fc portion derived from an immunoglobulin of a first subclass (e.g., IgG4 subclass) (e.g., a complete Fc portion) and an Fc portion derived from an immunoglobulin of a second subclass (e.g., IgG1, IgG2, or IgG3 subclass). For example, the Fc region or portion may include a CH2 domain derived from IgG4 immunoglobulin and a CH3 domain derived from IgG1 immunoglobulin.For example, the Fc region or portion may include the CH1 and CH2 domains derived from the IgG4 molecule and the CH3 domain derived from the IgG1 molecule. For example, the Fc region or portion may include a portion of the CH2 domain derived from a particular subclass of the antibody, for example, the CH2 domain at EU positions 292-340. For example, the Fc region or portion may include the amino acids at positions 292-340 of CH2 derived from the IgG4 portion and the remainder of CH2 derived from the IgG1 portion (or CH2 at positions 292-340 which may be derived from the IgG1 portion, and the remainder of CH2 which may be derived from the IgG4 portion).

[0110] Furthermore, the Fc region or portion may (alternatively or in addition) include, for example, a chimeric hinge region. For example, the chimeric hinge may be, for example, partially derived from an IgG1, IgG2, or IgG4 molecule (e.g., upper and lower-mid hinge sequences) and partially derived from an IgG3 molecule (e.g., central hinge sequence). In another embodiment, the Fc region or portion may include a chimeric hinge partially derived from an IgG1 molecule and partially derived from an IgG4 molecule. In another embodiment, the chimeric hinge may include upper and lower hinge domains derived from an IgG4 molecule and a mid-hinge domain derived from an IgG1 molecule. Such a chimeric hinge may be prepared, for example, by introducing a proline substitution (Ser228Pro) at EU position 228 of the mid-hinge domain of the IgG4 hinge region. In other embodiments, the chimeric hinge may include amino acids at EU positions 233-236, wherein the amino acids are derived from the IgG2 antibody and / or the Ser228Pro mutation, and the remaining amino acids of the hinge are derived from the IgG4 antibody (e.g., the chimeric hinge of sequence ESKYGPPCPPCPAPPVAGP). Further chimeric hinges that may be used in the Fc portion of the antibody according to the present invention are described in US2005 / 0163783A1.

[0111] In some embodiments, the Fc portion or Fc region contains or is composed of an amino acid sequence derived from a human immunoglobulin sequence (e.g., an Fc region or Fc portion derived from a human IgG molecule). However, the polypeptide may contain one or more amino acids derived from another mammalian species. For example, a primate Fc portion or primate binding site may be included in the polypeptide in question. Alternatively, one or more mouse amino acids may be present in the Fc portion or Fc region.

[0112] In some embodiments, the antibody according to the present invention includes, in particular, the Fc portion described above, other portions derived from a constant region, particularly the constant region of IgG, for example, the constant region of (human) IgG1. The antibody according to the present invention may include, in particular, all other portions of the constant region, particularly all other portions of the constant region of IgG (e.g., (human) IgG1), in addition to the Fc portion described above.

[0113] Examples of constant region sequences are amino acid sequences following SEQ ID NOs. 35-37. For example, the amino acid sequence of IgG1 CH1-CH2-CH3 follows SEQ ID NO: 35 or its sequence variants (e.g., including one, two, three, four, five, six, seven, eight, nine, ten, or more mutations) and has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity.

[0114] As outlined above, the antibody according to the present invention may include a (complete) Fc region derived from human IgG1. In some embodiments, the antibody according to the present invention includes, in particular, all other parts of the constant region of IgG, including all other parts of the constant region of (human) IgG1, in addition to the (complete) Fc region derived from human IgG1.

[0115] In some embodiments, the antibody according to the present invention includes a (complete) Fc portion / region, and its interaction / binding with FcR is not impaired. Generally, antibody binding to the Fc receptor can be performed by various methods known to those skilled in the art, such as ELISA (Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, Lanigan CMS, Landucci G, Forthal DN, Parren PWHI, et al.: Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104; Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT: Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions. 2015, 194:5497-5508) or flow cytometry (Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC: Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.J Virol 2009, 83:7397-7410; Piccoli L, Campo I, Fregni CS, Rodriguez BMF, Minola A, Sallusto F, Luisetti M, Corti D, Lanzavecchia A: Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. .

[0116] Generally, the antibodies according to the present invention may be glycosylated. N-linked glycans bound to the CH2 domain of the heavy chain can affect binding to, for example, glycosylated antibodies of C1q and FcR (which have lower affinity for these receptors). Therefore, the CH2 domain of the Fc portion of the antibody according to the present invention may contain one or more mutations in which a glycosylated residue is replaced by a non-glycosylated residue. For example, the glycan of the antibody does not evoke a human immunogenic response after administration.

[0117] Furthermore, antibodies according to the present invention can be modified by introducing (random) amino acid mutations into specific regions of the CH2 or CH3 domain of the heavy chain to alter their binding affinity to FcR and / or their serum half-life compared to unmodified antibodies. Examples of such modifications include, but are not limited to, the substitution of at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428. Further examples of such Fc modifications are described in Saxena A, Wu D. Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life. Front Immunol. 2016;7:580, which is incorporated herein by reference. In some embodiments, the antibody may contain a "YTE" mutation (M252Y / S254T / T256E; EU numbering). In some embodiments, the antibody may contain the mutation M428L and / or N434S in the heavy chain constant region (EU numbering).

[0118] The antibodies of the present invention also include a hybrid antibody molecule comprising six CDRs derived from the antibody of the present invention as defined above, and one or more CDRs derived from another antibody against an antigen. For example, the antibody may be bispecific. A bispecific (or multispecific) antibody or its antigen-binding fragment according to the present invention may contain at least one specificity (antigen-binding site of the antibody) as described herein. In some embodiments, a bispecific (or multispecific) antibody or its antigen-binding fragment binds to two different epitopes of the MPV F protein. For this purpose, the specificities of two different antibodies of the present invention may be combined, for example, as described below for antibody combinations (however, instead of a “cocktail”, a bispecific-or multispecific antibody may possess the combined specificity).

[0119] Mutant antibodies are also included within the scope of the present invention. Accordingly, variants of the sequences listed in this application are also included within the scope of the present invention. Such variants include native variants that are produced by somatic mutations in vivo during an immune response or in vitro during the culture of immortalized B cell clones. Alternatively, variants may arise due to degeneracy of the gene code or be produced due to errors in transcription or translation.

[0120] The antibodies of the present invention may be provided in a purified form. Typically, the antibodies are present in a composition that is substantially free of other polypeptides, for example, less than 90% (by weight), usually less than 60%, and more usually less than 50% of the composition consists of other polypeptides.

[0121] The antibodies of the present invention may be immunogenic in non-human (or heterologous) hosts, such as mice. In particular, the antibodies may have an idiotope that is immunogenic in non-human hosts but not immunogenic in human hosts. In particular, the antibodies of the present invention for use in humans include those that cannot be easily isolated from hosts such as mice, goats, rabbits, rats, and non-primate mammals, and that cannot generally be obtained by humanization or from xenomuse.

[0122] (nucleic acid) In another embodiment, the present invention also provides nucleic acid molecules comprising polynucleotides encoding the antibody or antigen-binding fragment thereof according to the present invention as described above.

[0123] In some embodiments, the nucleic acid molecule comprises one or more polynucleotides encoding the exemplary antibodies of the present invention as described herein (for example, as listed in Table 1 above), or sequence variants thereof (for example, having at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity as described above).

[0124] Table 2 below shows exemplary nucleic acid sequences encoding the CDR and VH / VL sequences of the exemplary antibody of the present invention.

[0125] [Table 2]

[0126] For example, a nucleic acid molecule may contain (i) or (ii): (i) the polynucleotide described in either SEQ ID NO: 45 or 54; and the polynucleotide described in either SEQ ID NO: 46 or 55; (ii) Polynucleotides as described in either SEQ ID NO: 38 or 47; polynucleotides as described in either SEQ ID NO: 39 or 48; polynucleotides as described in either SEQ ID NO: 40 or 49; polynucleotides as described in either SEQ ID NO: 41 or 50; polynucleotides as described in either SEQ ID NO: 42, 43, 51, or 52; and polynucleotides as described in either SEQ ID NO: 44 or 53.

[0127] Examples of nucleic acid molecules and / or polynucleotides include recombinant polynucleotides, vectors, oligonucleotides, RNA molecules (such as rRNA, mRNA, miRNA, siRNA, or tRNA), or DNA molecules (such as cDNA). The nucleic acid may encode the light and / or heavy chain of an antibody. In other words, the light and heavy chains of an antibody may be encoded by the same nucleic acid molecule (e.g., by a bisistron method). Alternatively, the light and heavy chains of an antibody may be encoded by different nucleic acid molecules.

[0128] Due to the redundancy of the genetic code, the present invention also includes sequence variants of nucleic acid sequences encoding the same amino acid sequence. Polynucleotides encoding an antibody (or complete nucleic acid molecule) may be optimized for antibody expression. For example, codon optimization of the nucleotide sequence may be used to improve the efficiency of translation in the expression system for antibody production. Furthermore, the nucleic acid molecule may contain heterologous components (i.e., components not found in nature) that are not present on the same nucleic acid molecule as the coding sequence for the antibody (heavy or light chain). For example, the nucleic acid molecule may contain heterologous promoters, heterologous enhancers, heterologous UTRs (e.g., for optimal translation / expression), heterologous poly-A-tails, etc.

[0129] A nucleic acid molecule is a molecule containing nucleic acid components. The term nucleic acid molecule usually refers to a DNA or RNA molecule. It may also be used synonymously with the term "polynucleotide," meaning that a nucleic acid molecule may consist of polynucleotides encoding antibodies. Alternatively, a nucleic acid molecule may also contain additional elements in addition to polynucleotides encoding antibodies. Typically, a nucleic acid molecule is a polymer consisting of nucleotide monomers covalently bonded to each other by phosphodiester bonds of a sugar / phosphate backbone. The term "nucleic acid molecule" also encompasses modified nucleic acid molecules, such as base-modified DNA or RNA molecules, sugar-modified DNA or RNA molecules, or backbone-modified DNA or RNA molecules.

[0130] In general, nucleic acid molecules may be manipulated to insert, delete, or modify specific nucleic acid sequences. Modifications resulting from such manipulations include, but are not limited to, modifications to introduce restriction sites, modifications to correct codon usage frequency, and modifications to add or optimize transcriptional and / or translational regulatory sequences. It is also possible to modify nucleic acids to alter the encoded amino acids. For example, it may be useful to introduce one or more amino acid substitutions, deletions, and / or insertions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.) into the amino acid sequence of an antibody. Such point mutations can alter effector function, antigen-binding affinity, post-translational modification, immunogenicity, etc., and can introduce amino acids for the addition of covalent groups (e.g., labels) or tags (e.g., for purification purposes). Alternatively, mutations in nucleic acid sequences may be "silent," meaning they may not be reflected in the amino acid sequence due to redundancy in the genetic code. In general, mutations can be introduced at specific sites or randomly and then selected (e.g., through molecular evolution). For example, one or more nucleic acids encoding either the light or heavy chain of an (exemplary) antibody can be randomly or specifically mutated to introduce different properties into the encoded amino acids. Such changes may be the result of an iterative process in which the initial change is retained and a new change is introduced at other nucleotide positions. Furthermore, changes achieved in independent steps may be combined.

[0131] In some embodiments, the polynucleotide (or (complete) nucleic acid molecule) encoding the antibody or its antigen-binding fragment may be codon-optimized. Those skilled in the art are aware of various tools for codon optimization, such as those described below: Ju Xin Chin, Bevan Kai-Sheng Chung, Dong-Yup Lee, Codon Optimization OnLine (COOL): a web-based multi-objective optimization platform for synthetic gene design, Bioinformatics, Volume 30, Issue 15, 1 August 2014, Pages 2210-2212; or in: Grote A, Hiller K, Scheer M, Munch R, Nortemann B, Hempel DC, Jahn D, JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W526-31; or, for example, Genscript's OptimumGene™ algorithm (described in US2011 / 0081708A1). For example, the nucleic acid molecule of the present invention may include any one of the nucleic acid sequences described in SEQ ID NOs: 38 to 55; or sequence variants thereof having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0132] The present invention also provides a combination of first and second nucleic acid molecules, the first nucleic acid molecule comprising a polynucleotide encoding the heavy chain of the antibody of the present invention or its antigen-binding fragment; and the second nucleic acid molecule comprising a polynucleotide encoding the corresponding light chain of the same antibody or its same antigen-binding fragment. The above description of the (general) features of the nucleic acid molecules of the present invention applies depending on the first and second nucleic acid molecules of the combination. Thus, one or both of the antibody heavy chain and / or the polynucleotide encoding the light chain or its antigen-binding fragment may be codon-optimized. For example, the combination may comprise the nucleic acid sequences described in any one of SEQ ID NOs. 38 to 55; or sequence variants thereof having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0133] The present invention also provides a combination of first and second nucleic acid molecules, -The first nucleic acid molecule comprises a polynucleotide encoding the heavy chain of an antibody or its antigen-binding fragment, the polynucleotide comprising (a) the nucleotide sequence described in SEQ ID NOs: 38, 39 and 40; or (b) the nucleotide sequence described in SEQ ID NOs: 47, 48 and 49; and - The second nucleic acid molecule comprises a polynucleotide encoding the light chain of an antibody or its antigen-binding fragment, the polynucleotide comprising (c) the nucleotide sequence described in SEQ ID NOs. 41, 42 (or 43) and 44; or (d) the nucleotide sequence described in SEQ ID NOs. 50, 51 (or 52) and 53.

[0134] Such combinations typically encode the antibody or antigen-binding fragment of the present invention described above. In this case as well, the above description of the (general) characteristics of the nucleic acid molecules of the present invention applies depending on the first and second nucleic acid molecules of the combination.

[0135] (vector) Further within the scope of the present invention are vectors containing nucleic acid molecules according to the present invention, such as expression vectors. Typically, vectors contain the above-mentioned nucleic acid molecules.

[0136] The present invention also provides a combination of first and second vectors, wherein the first vector comprises the first nucleic acid molecule (for a combination of nucleic acid molecules) described above, and the second vector comprises the second nucleic acid molecule (for a combination of nucleic acid molecules) described above.

[0137] Vectors are typically recombinant nucleic acid molecules, i.e., nucleic acid molecules that do not exist in nature. Therefore, vectors may contain heterologous elements (i.e., sequence elements of different origins in nature). For example, a vector may contain multi-cloning sites, heterologous promoters, heterologous enhancers, heterologous selection markers (for identifying cells containing the vector compared to cells without the vector), etc. Vectors in the context of the present invention are suitable for incorporating or retaining desired nucleic acid sequences. Such vectors may be conservation vectors, expression vectors, cloning vectors, transfer vectors, etc. Conservation vectors are vectors that allow for convenient storage of nucleic acid molecules. Therefore, a vector may contain, for example, a sequence corresponding to a desired antibody (heavy and / or light chain) according to the present invention. Expression vectors may be used for the production of expression products such as RNA, e.g., mRNA, or peptides, polypeptides, or proteins. For example, an expression vector may contain sequences necessary for the transcription of the vector's sequence stretch, such as (heterologous) promoter sequences. Cloning vectors are typically vectors that contain cloning sites that can be used to incorporate nucleic acid sequences into the vector. The cloning vector may be, for example, a plasmid vector or a bacteriophage vector. The transcription vector may be a vector suitable for transcribing nucleic acid molecules into cells or organisms, such as a viral vector. The vector in the context of the present invention may be, for example, an RNA vector or a DNA vector. For example, the vector in the sense of this application includes a cloning site, a selection marker such as an antibiotic resistance factor, and a sequence suitable for vector proliferation, such as an origin of replication. The vector in the context of this application may be a plasmid vector.

[0138] (cell) In a further embodiment, the present invention also provides cells expressing an antibody or an antigen-binding fragment thereof according to the present invention; and / or cells comprising a vector (or combination of vectors) according to the present invention.

[0139] Examples of such cells include, but are not limited to, eukaryotic cells, such as yeast cells, animal cells, or plant cells. Other examples of such cells include, but are not limited to, prokaryotic cells, such as Escherichia coli. In some embodiments, the cells are mammalian cells, such as mammalian cell lines. Examples include human cells, CHO cells, HEK293T cells, PER.C6 cells, NS0 cells, human hepatocytes, myeloma cells, or hybridoma cells.

[0140] Cells may be transfected with vectors according to the present invention, such as expression vectors. The term “transfection” refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g., mRNA) molecules, into cells, such as eukaryotic or prokaryotic cells. In the context of the present invention, the term “transfection” encompasses any method known to those skilled in the art for introducing nucleic acid molecules into cells, such as mammalian cells. Such methods include, for example, electroporation, lipofection (e.g., based on cationic lipids and / or liposomes), calcium phosphate precipitation, nanoparticle-based transfection, virus-based transfection, or cationic polymer-based transfection (e.g., DEAE-dextran or polyethyleneimine). In some embodiments, the introduction is nonviral.

[0141] Furthermore, the cells of the present invention may be stably or transiently transfected with a vector according to the present invention, for example, to express an antibody according to the present invention. In some embodiments, the cells are stably transfected with a vector according to the present invention encoding an antibody according to the present invention. In other embodiments, the cells are transiently transfected with a vector according to the present invention encoding an antibody according to the present invention.

[0142] Accordingly, the present invention also provides recombinant host cells that heterologously express the antibody or its antigen-binding fragment. For example, the cells may be of a different species other than the antibody (e.g., CHO cells expressing human antibodies). In some embodiments, the cell type of the cells does not express such antibodies in nature. Furthermore, the host cells may confer post-translational modifications (PTMs; e.g., glycosylation) to the antibodies that do not exist in their natural state. Such PTMs may result in functional differences (e.g., reduced immunogenicity). Therefore, the antibody or its antigen-binding fragment may have post-translational modifications different from those of naturally produced antibodies (e.g., antibodies in the immune response in humans).

[0143] (Antibody production) The antibodies according to the present invention can be produced by any method known in the art. For example, general methodologies for producing monoclonal antibodies using hybridoma technology are well known (Kohler, G. and Milstein, C., 1975; Kozbar et al. 1983). In some embodiments, alternative EBV immortalization methods described in WO2004 / 076677 are used.

[0144] In some embodiments, the method described in WO2004 / 076677, incorporated herein by reference, is used. In this method, B cells producing the antibody of the present invention are transformed with EBV and a polyclonal B cell activator. Further stimulants for cell proliferation and differentiation may be optionally added during the transformation step to further enhance efficiency. These stimulants may be cytokines such as IL-2 and IL-15. In one embodiment, IL-2 is added during the immortalization step to further improve the efficiency of immortalization, although its use is not essential. The immortalized B cells produced using these methods can then be cultured using methods known in the art and antibodies isolated therefrom.

[0145] Another exemplary method is described in WO2010 / 046775. In this method, plasma cells are cultured in a limited number or as single plasma cells in a microwell culture plate. Antibodies can be isolated from the plasma cell culture. Furthermore, RNA can be extracted from the plasma cell culture and subjected to PCR using methods known in the art. The VH and VL regions of the antibody can be amplified by RT-PCR (reverse transcriptase PCR), sequenced, cloned into an expression vector, and then transfected into HEK293T cells or other host cells. Cloning of nucleic acids in the expression vector, transfection of host cells, culture of the transfected host cells, and isolation of the produced antibody can be carried out using any method known to those skilled in the art.

[0146] If necessary, antibodies can be further purified using filtration, centrifugation, and various chromatographic methods (such as HPLC or affinity chromatography). Techniques for purifying antibodies, such as monoclonal antibodies (including techniques for producing pharmaceutical-grade antibodies), are well known in the art.

[0147] The DNA sequence encoding the antibody of the present invention may be prepared using standard molecular biology techniques. The desired DNA sequence may be synthesized completely or partially using oligonucleotide synthesis techniques. Site-directed mutagenesis and polymerase chain reaction (PCR) techniques may be used as needed.

[0148] Any suitable host cell / vector system may be used for the expression of the DNA sequence encoding the antibody molecule of the present invention. Eukaryotic, for example, mammalian host cell expression systems may be used for the production of antibody molecules, such as complete antibody molecules. Suitable mammalian host cells include, but are not limited to, CHO cells, HEK293T cells, PER.C6 cells, NS0 cells, myeloma cells, or hybridoma cells. Prokaryotic, for example, bacterial host cell expression systems may also be used for the production of antibody molecules, such as complete antibody molecules. Suitable bacterial host cells include, but are not limited to, Escherichia coli cells.

[0149] The present invention also provides a method for producing an antibody molecule according to the present invention, comprising the steps of culturing (heterogeneous) host cells containing a vector encoding the nucleic acid of the present invention under conditions suitable for the expression of a protein from DNA encoding the antibody molecule of the present invention, and isolating the antibody molecule.

[0150] For the production of antibodies containing both heavy and light chains, the cell line may be transfected with two vectors: a first vector encoding a light chain polypeptide and a second vector encoding a heavy chain polypeptide. Alternatively, a single vector may be used, which contains sequences encoding both the light chain polypeptide and the heavy chain polypeptide.

[0151] The antibody according to the present invention may be produced by (i) expressing the nucleic acid sequence according to the present invention in a host cell, for example, by using a vector according to the present invention, and (ii) isolating the expressed antibody product. Furthermore, the method may include (iii) purifying the isolated antibody. Transformed B cells and cultured plasma cells may be screened for those that produce antibodies of desired specificity or function.

[0152] The screening step may be performed by any immunoassay, e.g., ELISA, by staining of tissues or cells (including transfected cells), by a neutralization assay, or by one of many other methods known in the art for identifying desired specificity or function. The assay may be selected based on the simple recognition of one or more antigens, or on an additional basis of desired function, for example, by selecting a neutralizing antibody rather than simply an antigen-binding antibody, to select an antibody that can modify the properties of target cells (e.g., their signaling cascade, their morphology, their growth rate, their ability to influence other cells, their response to influence by other cells, other reagents or changes in conditions, their differentiation state, etc.).

[0153] Subsequently, individual transformed B cell clones may be produced from a positive transformed B cell culture. The cloning step for isolating individual clones from a mixture of positive cells may be performed by limiting dilution, micromanipulation, single-cell deposition by cell sorting, or by other methods known in the art.

[0154] Nucleic acids from cultured plasma cells can be isolated, cloned, and expressed in HEK293T cells or other known host cells using methods known in the art.

[0155] The immortalized B cell clones or transfected host cells of the present invention can be used in a variety of applications, such as a source of monoclonal antibodies, a source of nucleic acids (DNA or mRNA) encoding the monoclonal antibody of interest, or for research purposes.

[0156] The present invention also provides a composition comprising immortalized B memory cells or transfected host cells that produce antibodies according to the present invention.

[0157] The immortalized B cell clones or cultured plasma cells of the present invention may also be used as nucleic acid sources for cloning antibody genes for subsequent recombinant expression. Expression from recombinant sources may be more common for pharmaceutical purposes than expression from B cells or hybridomas for reasons such as stability, reproducibility, and ease of culture.

[0158] Accordingly, the present invention also provides a method for preparing recombinant cells, comprising: (i) obtaining one or more nucleic acids (e.g., heavy chain and / or light chain mRNA) from a B cell clone or a cultured plasma cell encoding an antibody of interest; (ii) inserting the nucleic acids into an expression vector; and (iii) transfecting the vector into a (heterogeneous) host cell to enable the expression of the antibody of interest in that host cell.

[0159] Similarly, the present invention also provides a method for preparing recombinant cells, comprising: (i) sequencing a nucleic acid from a B cell clone or cultured plasma cell encoding an antibody of interest; and (ii) using the sequence information from step (i) to prepare a nucleic acid for insertion into a host cell to enable the expression of the antibody of interest in that host cell. The nucleic acid may, but is not necessarily, be manipulated between steps (i) and (ii) to introduce restriction sites, alter codon usage frequency, and / or optimize transcriptional and / or translational regulatory sequences.

[0160] Furthermore, the present invention also provides a method for preparing transfected host cells, comprising the step of transfecting host cells with one or more nucleic acids encoding an antibody of interest, wherein the nucleic acids are nucleic acids derived from immortalized B cell clones or cultured plasma cells of the present invention. Thus, the procedure for first preparing the nucleic acids and then transfecting host cells with them can be carried out by different people at different times in different locations (e.g., in different countries).

[0161] These recombinant cells of the present invention can then be used for expression and culture purposes. They are particularly useful for antibody expression for large-scale pharmaceutical production. They can also be used as active ingredients in pharmaceutical compositions. Any suitable culture technique can be used (including, but not limited to, static culture, roller bottle culture, ascites fluid, hollow fiber bioreactor cartridges, modular mini-fermenters, agitated tanks, microcarrier culture, ceramic core perfusion, etc.).

[0162] Methods for obtaining and sequencing immunoglobulin genes from B cells or plasma cells are well known in the art (see, for example, Chapter 4 of Kuby Immunology, 4th edition, 2000).

[0163] The transfected host cells may be eukaryotic cells, including yeast cells and animal cells, particularly mammalian cells (e.g., CHO cells, NS0 cells, PER. human cells (such as PER. C6 or HKB-11 cells), myeloma cells, or human hepatocytes), as well as plant cells. In some embodiments, the transfected host cells are mammalian cells such as human cells. In some embodiments, the expression host can glycosylate the antibody of the present invention, particularly with a carbohydrate structure that is not immunogenic in itself in humans. In some embodiments, the transfected host cells can be grown in serum-free medium. In further embodiments, the transfected host cells can be grown in a culture that does not contain animal-derived products. The transfected host cells may be cultured to obtain a cell line.

[0164] The present invention also provides a method for preparing one or more nucleic acid molecules (e.g., heavy chain and light chain genes) encoding a target antibody, comprising the steps of (i) preparing an immortalized B cell clone or culturing plasma cells according to the present invention; and (ii) obtaining nucleic acid encoding a target antibody from a B cell clone or cultured plasma cell. Furthermore, the present invention provides a method for obtaining a nucleic acid sequence encoding a target antibody, comprising the steps of (i) preparing an immortalized B cell clone or culturing plasma cells according to the present invention; and (ii) sequencing nucleic acid from a B cell clone or cultured plasma cell encoding a target antibody.

[0165] The present invention further provides a method for preparing a nucleic acid molecule encoding a target antibody, comprising the step of obtaining the obtained nucleic acid from transformed B cell clones or cultured plasma cells according to the present invention. Thus, the procedure for first obtaining B cell clones or cultured plasma cells and then obtaining nucleic acid from B cell clones or cultured plasma cells can be carried out by different people at different locations (e.g., in different countries) at different times.

[0166] The present invention also includes a method for preparing an antibody (for example, for pharmaceutical use) according to the present invention, comprising the steps of (i) obtaining and / or sequencing one or more nucleic acids (e.g., heavy chain and light chain genes) from a selected B cell clone or cultured plasma cell that expresses the antibody of interest; (ii) inserting nucleic acids or preparing an expression vector using nucleic acids; (iii) transfecting a host cell capable of expressing the antibody of interest; (iv) culturing or subculturing the transfected host cell under conditions in which the antibody of interest is expressed; and optionally, (v) purifying the antibody of interest.

[0167] The present invention also provides a method for preparing an antibody of interest, comprising the steps of: culturing or subculturing a transfected host cell population, for example, a stably transfected host cell population, under conditions in which the antibody of interest is expressed; and optionally, producing the antibody of interest, wherein the transfected host cell population is prepared by (i) providing a nucleic acid encoding the antibody of interest to be produced by a B cell clone or cultured plasma cell prepared as described above; (ii) inserting the nucleic acid into an expression vector; (iii) transfecting the vector into host cells capable of expressing the antibody of interest; and (iv) culturing or subculturing the transfected host cells containing the inserted nucleic acid to produce the antibody of interest. Therefore, the procedure of first preparing recombinant host cells and then culturing them to express an antibody can be performed by different people in different locations (e.g., in different countries) at very different times.

[0168] (Pharmaceutical composition) The present invention also provides a pharmaceutical composition comprising one or more of the following: (i) The antibody of the present invention or its antigen-binding fragment; (ii) nucleic acids or combinations of nucleic acids according to the present invention; (iii) The vector or combination of vectors of the present invention; and / or (iv) Cells expressing the antibody according to the present invention, or cells containing the vector according to the present invention And, optionally, pharmaceutically acceptable excipients, diluents, or carriers.

[0169] In other words, the present invention also provides pharmaceutical compositions comprising antibodies according to the present invention, nucleic acids according to the present invention, vectors according to the present invention, and / or cells according to the present invention.

[0170] The pharmaceutical composition may also optionally contain pharmaceutically acceptable carriers, diluents, and / or excipients. While carriers or excipients may facilitate administration, they should not themselves induce the production of antibodies harmful to individuals receiving the composition. They should also be non-toxic. Suitable carriers may be large, slowly metabolized macromolecules such as proteins, polypeptides, liposomes, polysaccharides, polylactic acid, polyglycolic acid, high molecular weight amino acids, amino acid copolymers, and inactive virus particles. In some embodiments, the pharmaceutically acceptable carriers, diluents, and / or excipients in the pharmaceutical composition according to the present invention are not active ingredients with respect to MPV infection.

[0171] Pharmaceutically acceptable salts may include, for example, mineral salts (such as hydrochlorides, hydrobroms, phosphates, and sulfates) or salts of organic acids (such as acetates, propions, malons, and benzoates).

[0172] A pharmaceutically acceptable carrier in a pharmaceutical composition may further include liquids such as water, saline solution, glycerol, and ethanol. Furthermore, auxiliary substances such as wetting agents, emulsifiers, or pH buffers may be present in such compositions. Such carriers enable the formulation of the pharmaceutical composition as tablets, pills, coated tablets, capsules, liquids, gels, syrups, slurries, and suspensions for administration by the subject.

[0173] The pharmaceutical compositions of the present invention may be prepared in various forms. For example, the composition may be prepared as an injectable, either as a liquid solution or a suspension. A solid form suitable for a solution or suspension in a liquid vehicle before injection may also be prepared (e.g., lyophilized compositions similar to Synagis® and Herceptin® for reconstitution with sterile water containing a preservative). The composition may be prepared for topical administration, for example, as an ointment, cream, or powder. The composition may be prepared for oral administration, for example, as a tablet or capsule, as a spray, or as a syrup (optionally flavored). The composition may be prepared for pulmonary administration, for example, using a fine powder or spray as an inhaler. The composition may be prepared as a suppository or pessary. The composition may be prepared for administration to the nose, ear, or eye, for example, as a drop. The composition may also be in the form of a kit, designed so that the combined composition is reconstituted immediately before administration to the subject. For example, lyophilized antibodies may be provided in the form of a kit with sterile water or sterile buffer.

[0174] In some embodiments, the (sole) active ingredient in the composition is the antibody according to the present invention. Therefore, it may be susceptible to degradation in the gastrointestinal tract. Thus, if the composition is administered via a route using the gastrointestinal tract, the composition may contain a drug that protects the antibody from degradation but releases the antibody once absorbed from the gastrointestinal tract.

[0175] A complete discussion of pharmaceutically acceptable carriers is available in Gennaro (2000) Remington: The Science and Practice of Pharmacy, 20th edition, ISBN: 0683306472.

[0176] The pharmaceutical compositions of the present invention generally have a pH of 5.5 to 8.5, and in some embodiments, this may be 6 to 8, for example, about 7. The pH may be maintained by the use of a buffer. The composition may be sterile and / or pyrogen-free. The composition may be isotonic to humans. In some embodiments, the pharmaceutical compositions of the present invention are supplied in airtight sealed containers.

[0177] The scope of the present invention includes compositions that exist in several dosage forms; these forms include, but are not limited to, those suitable for parenteral administration, such as by injection or infusion, e.g., by bolus injection or serial infusion. When the product is for injection or infusion, it may take the form of a suspension, solution, or emulsion in an oily or aqueous vehicle, and may contain formulations such as suspending agents, preservatives, stabilizers, and / or dispersants. Alternatively, the antibody may be in a dry form for reconstitution with a suitable sterile liquid before use.

[0178] A vehicle is typically understood to be a material suitable for storing, transporting, and / or administering compounds, such as pharmaceutically active compounds, particularly antibodies according to the present invention. For example, the vehicle may be a physiologically acceptable liquid suitable for storing, transporting, and / or administering pharmaceutically active compounds, particularly antibodies according to the present invention. Once formulated, the compositions of the present invention can be administered directly to a subject. In some embodiments, the compositions are applied to administration to mammals, such as human subjects.

[0179] The pharmaceutical compositions of the present invention may be administered by any number of routes (including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intraperitoneal, intrathecal, intraventricular, percutaneous, transcutaneous, topical, subcutaneous, intranasal, enteral, sublingual, vaginal, or rectal routes). Hypospray may also be used to administer the pharmaceutical compositions of the present invention. Optionally, the pharmaceutical compositions may be prepared for oral administration (e.g., as tablets, capsules, etc., for topical administration) or as injections (e.g., as liquid solutions or suspensions). In some embodiments, the pharmaceutical compositions are injections. Solid forms suitable for solutions or suspensions in a liquid vehicle before injection are also included; for example, the pharmaceutical compositions may be in lyophilized form.

[0180] For injection, e.g., intravenous, cutaneous, or subcutaneous injection, or injection at the site of pain, the active ingredient may be pyrogen-free and in the form of a parenterally acceptable aqueous solution having appropriate pH, isotonicity, and stability. Those skilled in the art can readily prepare a suitable solution using, for example, an isotonic vehicle (such as sodium chloride injection, Ringer's injection, or Ringer's lactate injection). Preservatives, stabilizers, buffers, antioxidants, and / or other additives may be included as needed. Whether it is an antibody, peptide, nucleic acid molecule, or another pharmaceutically useful compound according to the present invention to be given individually, the administration is usually an "effective dose," e.g., a "prophylactic effective dose" or a "therapeutic effective dose" (in some cases), which is sufficient to show individual benefit. The actual amount administered, as well as the rate and time course of administration, depends on the nature and severity of what is being treated. For injection, the pharmaceutical composition according to the present invention may be provided, for example, in a pre-filled syringe.

[0181] The pharmaceutical compositions of the present invention as defined above may also be administered orally in any orally acceptable dosage form (including, but not limited to, capsules, tablets, aqueous suspensions, or solutions). For tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also typically added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When an aqueous suspension is required for oral use, the active ingredient, i.e., the transporter cargo conjugate molecule of the present invention as defined above, is combined with emulsifiers and suspending agents. Optionally, certain sweeteners, flavorings, or colorings may also be added.

[0182] The pharmaceutical compositions of the present invention may also be administered topically, particularly when the therapeutic target includes a region or organ that is easily accessible by topical application (e.g., accessible epithelial tissue). Suitable topical formulations are readily prepared for each of these regions or organs. For topical application, the pharmaceutical compositions of the present invention may be formulated in a suitable ointment containing the pharmaceutical compositions of the present invention, in particular, its components as defined above, suspended or dissolved in one or more carriers. Suitable carriers for topical administration include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying waxes, and water. Alternatively, the pharmaceutical compositions of the present invention can be formulated into a suitable lotion or cream. In the context of the present invention, suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.

[0183] The drug therapy may be a single-dose schedule or a multi-dose schedule. In particular, the pharmaceutical composition may be provided as a single-dose product. In some embodiments, the amount of antibody in the pharmaceutical composition—especially when provided as a single-dose product—does not exceed 200 mg, for example, not exceeding 100 mg or 50 mg.

[0184] For a single dose, for example, daily, weekly, or monthly administration, the amount of antibody in the pharmaceutical composition according to the present invention does not need to exceed 1 g or 500 mg. In some embodiments, for a single dose, the amount of antibody in the pharmaceutical composition according to the present invention does not need to exceed 200 mg or 100 mg. For example, for a single dose, the amount of antibody in the pharmaceutical composition according to the present invention does not need to exceed 50 mg.

[0185] A pharmaceutical composition typically contains an "effective" amount of one or more antibodies of the present invention, i.e., an amount sufficient to treat, improve, attenuate, reduce, or prevent a desired disease or condition, or to exhibit a detectable therapeutic effect. Therapeutic effects also include reduction or attenuation of pathogenic potency or physical symptoms. The exact effective dose for any particular subject depends on their size, weight, and health, the nature and degree of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The effective dose for a given situation is determined by routine experimentation and is within the scope of clinician judgment. For the purposes of the present invention, the effective dose may generally be about 0.005 to about 100 mg / kg, for example, about 0.0075 to about 50 mg / kg or about 0.01 to about 10 mg / kg. In some embodiments, the effective dose is about 0.02 to about 5 mg / kg of the antibody of the present invention (e.g., the amount of antibody in the pharmaceutical composition) with respect to the individual body weight (e.g., kg) to which it is administered.

[0186] Furthermore, the pharmaceutical composition according to the present invention may also contain further active ingredients, which may be further antibodies or non-antibody components. Therefore, the pharmaceutical composition according to the present invention may contain one or more additional active ingredients.

[0187] The antibody according to the present invention may be present in either of the same pharmaceutical compositions as the additional active ingredient, or the antibody according to the present invention may be included in a first pharmaceutical composition and the additional active ingredient in a second pharmaceutical composition different from the first pharmaceutical composition. Therefore, if two or more additional active ingredients are envisioned, each additional active ingredient and the antibody according to the present invention may be included in different pharmaceutical compositions. Such different pharmaceutical compositions may be administered in combination / simultaneously, at different times, or at different locations (e.g., different parts of the body).

[0188] The antibodies and additional active ingredients according to the present invention may provide additive therapeutic effects, such as synergistic therapeutic effects. The term “synergistic” is used to describe the combined effect of two or more activators that is greater than the sum of the individual effects of each activator. Thus, when the combined effect of two or more drugs results in “synergistic inhibition” of activity or process, it is intended that the inhibition of activity or process is greater than the sum of the inhibitory effects of each individual activator. The term “synergistic therapeutic effect” refers to the therapeutic effect observed in a combination of two or more treatments, where the therapeutic effect (measured by one of many parameters) is greater than the sum of the individual therapeutic effects observed in each individual treatment.

[0189] In other embodiments, the pharmaceutical composition according to the present invention may not contain additional active ingredients (in addition to the antibodies of the present invention, or their respective nucleic acids, vectors, or cells).

[0190] In some embodiments, the composition of the present invention may contain the antibody of the present invention, which may constitute at least 50% by weight of the total protein in the composition (e.g., 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more). In the composition of the present invention, the antibody may be in a purified form.

[0191] The present invention also provides a method for preparing a pharmaceutical composition, comprising the steps of (i) preparing an antibody of the present invention; and (ii) mixing the purified antibody with one or more pharmaceutically acceptable excipients, diluents, or carriers.

[0192] In other embodiments, a method for preparing a pharmaceutical composition comprises the step of mixing an antibody with one or more pharmaceutically acceptable carriers, wherein the antibody is a monoclonal antibody obtained from transformed B cells or cultured plasma cells of the present invention.

[0193] Instead of delivering antibodies or B cells for therapeutic purposes, nucleic acids (typically DNA) encoding the desired monoclonal antibody derived from B cells or cultured plasma cells can be delivered to the target, and as a result, the nucleic acid can be expressed in situ in the target to provide the desired therapeutic effect. Appropriate gene therapies and nucleic acid delivery vectors are known in the art.

[0194] Pharmaceutical compositions may contain antimicrobial agents, especially when packaged in multi-dose formats. They may also contain surfactants (e.g., Tween (polysorbate) (e.g., Tween 80)). Surfactants are generally present at low levels (e.g., less than 0.01%). The composition may also contain a sodium salt (e.g., sodium chloride) to provide isotonicity. For example, a concentration of NaCl of 10 ± 2 mg / ml is typical.

[0195] Furthermore, the pharmaceutical compositions may contain, for example, 15-30 mg / ml (e.g., 25 mg / ml) of a sugar alcohol (e.g., mannitol) or disaccharide (e.g., sucrose or trehalose) or disaccharide (e.g., sucrose or trehalose) per 10-30 mg / ml. The pH of the composition for lyophilization may be adjusted to around 5-8, or 5.5-7, or 6.1 before lyophilization.

[0196] The compositions of the present invention may also contain one or more immunomodulators. In some embodiments, one or more immunomodulators include an adjuvant.

[0197] (Combination of antibodies) In further embodiments, the present invention also provides combinations of distinct antibodies or their antigen-binding fragments that bind to (and neutralize) the MPV F protein. In particular, the antibodies in such combinations may bind to different epitopes of the MPV F protein. Whether the antibodies bind to the same or different epitopes can be determined, for example, by using competing studies known to those skilled in the art (and as described in the following examples).

[0198] In some embodiments, the combination of an antibody or its antigen-binding fragment includes: -An antibody or antigen-binding fragment according to the present invention as described above; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0199] Therefore, the combination of antibodies or their antigen-binding fragments may include the following: -(i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, the above-mentioned antibody or its antigen-binding fragment; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0200] For example, a combination of an antibody or its antigen-binding fragment may include the following: -Antibodies or antigen-binding fragments thereof as described herein, comprising the heavy chain CDR1, CDR2, and CDR3 sequences of antibody MPF5 (MPF5_VH117D), as well as the light chain CDR1, CDR2, and CDR3, or variants thereof; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0201] More specifically, the combination of antibodies or their antigen-binding fragments may include the following: -The antibody or its antigen-binding fragment, comprising the VH sequence and VL sequence of the antibody MPF5 (MPF5_VH117D) as described herein, or sequence variants thereof; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0202] Furthermore, the combination of antibodies or their antigen-binding fragments may include the following: -(i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 18, respectively, or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 18, respectively, comprising the above-mentioned antibody or its antigen-binding fragment; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0203] For example, a combination of an antibody or its antigen-binding fragment may include the following: -The antibody or its antigen-binding fragment comprising the heavy chain CDR1, CDR2, and CDR3 sequences of antibody MPE33 as described herein, and light chain CDR1, CDR2, and CDR3, or variants thereof; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0204] More specifically, the combination of antibodies or their antigen-binding fragments may include the following: -The antibody or its antigen-binding fragment, comprising the VH sequence and VL sequence of antibody MPE33 as described herein, or sequence variants thereof; and -An antibody or its antigen-binding fragment that binds to the MPV F protein (or a distinct epitope thereof).

[0205] In particular, the combination of an antibody or its antigen-binding fragment may include two different antibodies or their antigen-binding fragments as described herein. Such antibodies or their antigen-binding fragments as described herein may be bound to different epitopes of the MPV F protein.

[0206] Therefore, the combination of antibodies or their antigen-binding fragments may include the following: -(i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, comprising the above-mentioned antibody or its antigen-binding fragment; and -(iii) Heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 18, respectively; or (iv) Heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 18, respectively, the above-mentioned antibody or its antigen-binding fragment.

[0207] For example, a combination of an antibody or its antigen-binding fragment may include the following: -Antibodies or antigen-binding fragments thereof as described herein, comprising the heavy chain CDR1, CDR2, and CDR3 sequences of antibody MPF5 (MPF5_VH117D), as well as the light chain CDR1, CDR2, and CDR3, or variants thereof; and - The antibody or its antigen-binding fragment as described herein, comprising the heavy chain CDR1, CDR2, and CDR3 sequences of antibody MPE33, as well as the light chain CDR1, CDR2, and CDR3, or sequence variants as described herein.

[0208] More specifically, the combination of antibodies or their antigen-binding fragments may include the following: -The antibody or its antigen-binding fragment, comprising the VH sequence and VL sequence of the antibody MPF5 (MPF5_VH117D) as described herein, or sequence variants thereof; and - The antibody or its antigen-binding fragment, comprising the VH sequence and VL sequence of the antibody MPE33 as described herein, or sequence variants thereof.

[0209] For example, an antibody or its antigen-binding fragment comprising heavy chain CDR1 described in SEQ ID NO: 1, heavy chain CDR2 described in SEQ ID NO: 2, and heavy chain CDR3 described in SEQ ID NO: 3 or 10; as well as light chain CDR1 described in SEQ ID NO: 4, light chain CDR2 described in SEQ ID NO: 5 or 6, and light chain CDR3 described in SEQ ID NO: 7; may be combined with an antibody or its antigen-binding fragment comprising heavy chain CDR1 described in any one of SEQ ID NOs: 12, 21, 23, 25, 27, 29, 31, or 33, heavy chain CDR2 described in SEQ ID NO: 13, and heavy chain CDR3 described in SEQ ID NO: 14; as well as light chain CDR1 described in SEQ ID NO: 15, light chain CDR2 described in SEQ ID NO: 16 or 17, and light chain CDR3 described in SEQ ID NO: 18.

[0210] More specifically, an antibody or its antigen-binding fragment containing VH as described in SEQ ID NO: 8 or 11 and VL as described in SEQ ID NO: 9 may be combined with an antibody or its antigen-binding fragment containing VH as described in SEQ ID NO: 19, 22, 24, 26, 28, 30, 32, or 34 and VL as described in SEQ ID NO: 20.

[0211] In the combination of antibodies or antigen-binding fragments of the present invention, the antibody or antigen-binding fragment may be provided in any of the above forms, for example, as a protein (antibody), a nucleic acid (encoding the antibody), a vector (containing the nucleic acid), or a cell (expressing the antibody or containing the vector). Accordingly, the present invention provides combinations including the following. (i) Two different antibodies of the present invention, or antigen-binding fragments thereof; (ii) Two different nucleic acids (or combinations of nucleic acids) of the present invention; (iii) Two different vectors (or combination of vectors) of the present invention; or (iv) Two distinct cells expressing two distinct antibodies according to the present invention, or containing two distinct vectors according to the present invention.

[0212] It is understood that combinations of the antibodies or antigen-binding fragments of the present invention (in any form described above, such as antibodies (proteins)) may be contained in the same composition or separate compositions (e.g., the pharmaceutical compositions described above). Accordingly, the present invention also provides pharmaceutical compositions comprising two different antibodies or antigen-binding fragments of the present invention as described above.

[0213] (Medical treatment and other uses) In a further embodiment, the present invention provides the pharmaceutical use of an antibody or its antigen-binding fragment according to the present invention, a nucleic acid molecule (or combination of nucleic acid molecules) according to the present invention, a vector (or combination of vectors) according to the present invention, a cell according to the present invention, or a pharmaceutical composition according to the present invention. In particular, an antibody or its antigen-binding fragment according to the present invention, a nucleic acid molecule (or combination of nucleic acid molecules) according to the present invention, a vector (or combination of vectors) according to the present invention, a cell according to the present invention, a pharmaceutical composition according to the present invention, or a combination of an antibody or its antigen-binding fragment according to the present invention may be used in the prevention and / or treatment of MPV infection; or (ii) in the diagnosis of MPV infection.

[0214] Accordingly, the present invention also provides a method for improving or reducing MPV infection or reducing the risk of MPV infection, comprising administering a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to the present invention, a nucleic acid molecule (or combination of nucleic acid molecules) according to the present invention, a vector (or combination of vectors) according to the present invention, a cell according to the present invention, or a pharmaceutical composition according to the present invention to a subject in need thereof. Furthermore, the present invention also provides the use of the antibody or antigen-binding fragment thereof according to the present invention, a nucleic acid molecule (or combination of nucleic acid molecules) according to the present invention, a vector (or combination of vectors) according to the present invention, a cell according to the present invention, a pharmaceutical composition according to the present invention, or a combination of the antibody or antigen-binding fragment thereof according to the present invention in the manufacture of a pharmaceutical for the prevention, treatment, or attenuation of MPV infection.

[0215] Prevention of MPV infection refers specifically to a preventive situation where the subject was not diagnosed with MPV (either no diagnosis was made or the diagnostic result was negative) and / or the subject did not exhibit symptoms of MPV infection. In contrast, a treatment situation is where the subject is typically diagnosed with MPV infection and / or exhibits symptoms of MPV infection. Notably, the terms “treatment” and “therapy” / “therapeutic” of MPV infection include (complete) cure and attenuation / reduction of MPV infection and / or related symptoms.

[0216] In some embodiments, the subject may be human. One method for testing the effectiveness of therapeutic treatment includes monitoring disease symptoms after administration of the composition of the present invention. The treatment may be a single-dose schedule or a multi-dose schedule. In one embodiment, the antibody, antibody fragment, nucleic acid, vector, cell, or composition according to the present invention is administered to a subject requiring such treatment. Such subjects include, but are not limited to, subjects at risk of or susceptible to MPV infection (e.g., immunocompromised subjects).

[0217] The antibodies and fragments described in the present invention may also be used for the diagnosis of MPV infection. The diagnostic method may include a step of contacting the antibody with a sample. Such a sample may be an isolated tissue sample taken from, for example, the nasal cavity, sinus cavity, salivary gland, lung, liver, pancreas, kidney, ear, eye, placenta, gastrointestinal tract, heart, ovary, pituitary gland, adrenal gland, thyroid gland, brain, skin, or blood (such as plasma or serum). For example, the antibody or its antigen-binding fragment may be contacted with an (isolated) blood sample (e.g., whole blood, plasma, or serum). The diagnostic method may also include the detection of an antigen / antibody complex, particularly after contact of the antibody with the sample. Such a detection step may typically be performed bench-side, i.e., without any contact with the human or animal body. Examples of detection methods are well known to those skilled in the art, and include, for example, ELISA (enzyme-linked immunosorbent assay). Thus, the diagnosis may be performed in vitro, for example, by using the isolated sample described above (and the in vitro detection step of the antigen / antibody complex). Therefore, antibodies or their antigen-binding fragments may be used in the (in vitro) diagnosis of MPV infection.

[0218] Therefore, the antibody or its antigen-binding fragment of the present invention may be used in an (in vitro) method for detecting the MPV antigen. Similarly, the antibody or its antigen-binding fragment of the present invention may be used in an (in vitro) method for binding an MPV target protein / antigen, such as the MPV F protein or its antigenic fragment or variant. Due to its specificity, the antibody or its antigen-binding fragment of the present invention recognizes the MPV F protein, particularly its pre-fusion conformation. To detect the MPV antigen, the antibody may be brought into contact with an (isolated) sample (i.e., a sample to be tested for the presence of the antigen). Specific binding of the antibody to its antigen (MPV F protein) forms an antibody / antigen complex, which can be readily detected by methods known in the art.

[0219] Such detection methods may be used in the context of (in vitro) diagnosis (using samples isolated from the human or animal body), but may also be used to test other (e.g., production / manufacturing) samples such as vaccine samples. Accordingly, the antibodies, antibody fragments, or variants thereof described in the present invention may also be used in non-therapeutic / non-diagnostic contexts (e.g., in vaccine development or manufacturing). Accordingly, the present invention also provides the use of the antibodies or antigen-binding fragments of the present invention for testing vaccines, in particular for testing whether the antigen (i.e., the desired antigen contained in the vaccine) is properly generated and / or folded (and / or in the correct conformation). Accordingly, the antibodies may be used to monitor the production of vaccines having the desired immunogenicity. For this purpose, the antibodies may be contacted with the vaccine, for example, as described above. Accordingly, the present invention also provides a method for testing an anti-MPV vaccine, in which the vaccine is contacted with the antibody or antigen-binding fragment, and optionally, the presence of the antibody / antigen complex is determined. Furthermore, the present invention also encompasses the use of the antibody or antigen-binding fragment of the present invention for monitoring the quality of an anti-MPV vaccine by testing whether the vaccine contains a desired antigen (e.g., the MPV F protein (e.g., in its pre-fusion conformation)) or a fragment or variant thereof. More specifically, the antibody may be used to test the conformation of the antigen or its epitope in the vaccine. Since the antibody of the present invention specifically binds to the pre-fusion F protein, the detection of a significant amount of antibody / antigen complex in a sample may mean that the sample contains the MPV F protein primarily in its pre-fusion conformation. Furthermore, variants of the antigen can also be tested using the antibody of the present invention (e.g., fragments and variants of the MPV F protein that may be useful in the vaccine).

[0220] [Brief explanation of the drawing] A brief description of the attached drawings is given below. The drawings are intended to illustrate the invention in more detail. However, they are not intended to limit the scope of the invention.

[0221] Figure 1 shows the binding characteristics of MPE33 and MPF5 antibodies to the hMPV F protein in the pre-fusion and post-fusion conformations compared to the reference antibody MPE8 for Example 1.

[0222] Figure 2 shows the neutralization of four different hMPV strains A1 / 6621 (MPV A1), A2 / VR8938 (MPV A2), B1 / VR4702 (MPV B1), and B2 / 3817 (MPV B2) with antibodies MPE33 and MPF5 compared to the reference antibody MPE8v3 in Example 2.

[0223] Figure 3 summarizes the EC50 values ​​required for neutralization of four different hMPV strains A1 / 6621 (MPV A1), A2 / VR8938 (MPV A2), B1 / VR4702 (MPV B1), and B2 / 3817 (MPV B2) with antibodies MPE33 and MPF5 compared to the reference antibody MPE8v3 for Example 2.

[0224] Figure 4 shows the binding affinity and EC50 values ​​of the antibodies MPF5_VH117D (MPF5), MPF5_VH117H, MPE33, and the comparative antibody MPE8v3 for the pre-fusion F protein of MPV in Example 3.

[0225] Figure 5 shows the VH and VL ("VK") sequences of the antibodies MPF5_VH117D (MPF5) and MPF5_VH117H. The squares indicate the position of substitution at amino acid position VH117.

[0226] Figure 6 shows the binding affinity and EC50 values ​​for the antibody MPE33, as well as its variants MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, and MPE33_N34S_C38Y, for the pre-fusion F protein of MPV in Example 4.

[0227] Figure 7 shows the VH and VL ("VK") sequences of the antibody MPE33. The squares indicate the positions of substitutions at amino acid positions N34, S36, and C38.

[0228] Figure 8 shows the binding of antibodies MPE33, MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, MPE33_N34S_C38Y, MPF5_VH117D (MPF5), MPF5_VH117H, and the comparative antibody MPE8 to the cell-bound F antigen of the hMPV strains MPV_NL / 1 / 99_F0-TM (top panel) and HMPV_Yokohama / JPN(P8527)2016 (interrupted panel) in Example 5. The lower panel shows the simulated transfection (control).

[0229] Figure 9 shows the results of a competitive test of antibodies MPF5, MPE33, and MPE8 for binding to the MPV F protein in Example 6. As expected, the data show competition among the same antibodies (MPF5 vs. MPF5; MPE33 vs. MPE33; MPE8 vs. MPE8). Furthermore, the panel MPF5 vs. MPE8 and the panel MPE8 vs. MPF5 demonstrate competition between MPF5 and MPE8. However, no competition was observed between MPE33 and MPE8, or between MPE33 and MPF5.

[0230] [Examples] The following describes specific examples illustrating various embodiments and aspects of the present invention. However, the present invention is not limited in scope by the specific embodiments described herein. The following preparations and examples are given to enable those skilled in the art to better understand and implement the present invention. However, the present invention is not limited in scope by the illustrated embodiments, which are intended only as illustrative examples of a single aspect of the present invention, and any functionally equivalent method is within the scope of the present invention. In fact, in addition to those described herein, various modifications of the present invention will be readily apparent to those skilled in the art from the foregoing description, the accompanying drawings, and the following examples. All such modifications fall within the scope of the appended claims.

[0231] (Example 1: Identification and characterization of human monoclonal antibodies MPF5 and MPE33) Human monoclonal antibodies against MPV, MPF5 (also known as "MPF5_VH117D") and MPE33, were isolated from human patients (see Traggiai E. et al., 2004, Nat Med 10(8): 871-5). The antibodies were characterized by determining the nucleotide and amino acid sequences of their variable regions (MPF5 VH: SEQ ID NO: 8, MPF5 VL: SEQ ID NO: 9; MPE33 VH: SEQ ID NO: 19, MPE33 VL: SEQ ID NO: 20), as well as their complementarity-determining regions (CRDs) (MPF5: SEQ ID NOs. 1-5 and 7, or 1-4, 6 and 7, respectively; MPE33: SEQ ID NOs. 12-16 and 18, or 12-15, 17 and 18, respectively). The VH and VL genes of MPF5 and MPE33 were cloned into an IgG1 expression vector, and recombinant antibodies were produced by transient transfection of 293Freestyle cells (293F). The supernatant was collected from the transfected cells, and IgG was affinity-purified by protein A chromatography. Thus, MPF5 and MPE33 are complete human monoclonal antibodies of type IgG1 having the CDR, VH, and VL sequences described herein.

[0232] To test the binding of MPF5 and MPE33 to the hMPV F protein, and to test the binding affinity of the antibodies to the hMPV F protein in pre-fusion versus post-fusion conformations, an ELISA assay was performed as essentially described in WO2016 / 103238A1. For comparison, the prior art antibody MPE8 (Corti et al., 2013, Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501: 439-443) was also tested in this experiment.

[0233] Briefly, Maxisorp ELISA plates were coated overnight with both conformationally stabilized pre- and post-fusion F protein antigens (F protein from CAN97-83 MPV strain, 1 μg / ml, 25 μl / well in PBS pH 7). After washing three times with PBS / Tween 0.01% (PBST), the test antibody was added starting at 10 μg / ml, titrated 3-fold to 11 points, and incubated at room temperature for 2 hours. The plates were then washed four times in PBST, and alkaline phosphatase-labeled goat anti-human IgG polyclonal antibody (SouthernBiotech, 2 μg / ml, 25 μl / well) was dispensed and incubated at RT for another 1 hour. After four washes in PBST, the plates were developed by adding 50 μl / well of AP substrate (pNPP, Sigma) in carbonate buffer and read at 405 nm after 45 minutes.

[0234] The results are shown in Figure 1. All tested antibodies (MPF5, MPE33, and MPE8) showed high binding affinity to the pre-fusion F protein of MPV, but not to the post-fusion F protein of MPV. Therefore, antibodies MPF5, MPE33, and MPE8 are specific to the pre-fusion F protein of MPV. The antibodies MPF5 and MPE33 of the present invention showed even lower EC50 values ​​compared to the prior art antibody MPE8, and therefore showed higher binding affinity to the pre-fusion F protein of MPV.

[0235] (Example 2: MPF5 and MPE33 effectively neutralize various strains of MPV) Next, the neutralization of various different strains of MPV was evaluated using the antibodies MPF5 and MPE33 of the present invention, as well as the comparative antibody MPE8v3, which is different from the control antibody MPE8 used in Example 1 in that it contains an N113S mutation in the heavy chain variable region to remove the glycosylation site.

[0236] Briefly, culture supernatants containing antibodies were analyzed using a micro-neutralization assay based on the infection of LLC-MK2 cells with hMPV strains A1 / 6621, A2 / VR8938, B1 / VR4702, and B2 / 3817. The neat supernatants were incubated with the virus at 0.239*10 6 TCID50 / ml (A1 / 6621), 0.0959*10 6 TCID50 / ml (A2 / VR8938), 0.33*l0 6 TCID50 / ml (B1 / VR4702) and 0.0959*10 6 TCID50 / ml (B2 / 3817) at room temperature for 1 hour, after which LLC-MK2 target cells were added and incubated for 14 days each. Viable cells were detected using the WST-1 reagent (Roche). The EC50 was measured using the above-described micro-neutralization assay with 10^0 TCID 50 of the virus, and virus infection was measured by indirect immunofluorescence using an automated pathway 855 analyzer (BD) on day 6 or day 7. The EC50 values were calculated by interpolation of a neutralization curve fitted with a four-parameter non-linear regression with a variable slope.

[0237] The results are shown in FIGS. 2 and 3. All antibodies effectively neutralized the four different MPV strains tested. Specifically, MPE33 and MPF5 showed significantly better neutralizing potency against the MPV B2 strain compared to the reference mAb MPE8v3.

[0238] (Example 3: The CDRH3 mutant of MPF5 shows similarly high binding affinity to the pre-fusion F protein of MPV.) Next, a mutant antibody of MPF5, MPF5_VH117H, was created. This differs from MPF5 in that its CDRH3 sequence is based on SEQ ID NO: 10 and its VH sequence is based on SEQ ID NO: 11. Figure 5 shows the differences in the heavy chain sequence and CDRH3 of MPF5.

[0239] The binding affinity of the antibodies MPF5_VH117D(MPF5), MPF5_VH117H, MPE8v3, and MPE33 to the pre-fusion F protein of MPV was tested using the ELISA assay described in Example 1.

[0240] The results are shown in Figure 4. All antibodies tested specifically bound to the pre-fusion F protein of MPV, but the binding affinities of the antibodies MPF5_VH117D(MPF5), MPF5_VH117H, and MPE33 were considerably higher than those of the comparative antibody MPE8v3. The similarly high binding affinities of antibodies MPF5_VH117D(MPF5) and MPF5_VH117H indicate that the CDRH3 mutation did not impair the binding affinity of MPF5 to the pre-fusion F protein of MPV.

[0241] (Example 4: The CDRH1 mutant of MPE33 shows similarly high binding affinity to the pre-fusion F protein of MPV.) Next, we prepared the following mutant antibodies of MPE33 that differ from MPE33 only in the shown CDRH1 sequence:

[0242] [Table 3]

[0243] Figure 7 shows the heavy chain sequence of MPE33 and the locations of the mutant amino acids in CDRH3.

[0244] The binding affinities of the antibody MPE33 and its mutant antibodies described above for the prefusion F protein of MPV were tested by the ELISA assay described in Example 1.

[0245] The results are shown in Fig. 6. All the tested antibodies MPE33, MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, and MPE33_N34S_C38Y specifically bound to the prefusion F protein of MPV with similarly high binding affinities. The binding affinities of all the mutant antibodies were slightly higher than that of MPE33 for the prefusion F protein of MPV, indicating that various CDRH1 mutations did not impair the binding affinity of MPE33 for the prefusion F protein of MPV.

[0246] (Example 5: Binding to cell-bound F antigen) Next, the binding of all the exemplified antibodies of the present invention described in the above examples as well as the comparative antibody MPE8 was tested.

[0247] For this purpose, Expi293 cells were transfected with MPV F proteins (MPV_NL / 1 / 99_F0-TM (AY304361) and HMPV_Yokohama / JPN (P8527) 2016). HMPV_Yokohama / JPN (P8527) 2016 harbors the D280N mutation. Briefly, 10 μg of plasmid DNA was diluted in 0.5 mL of Opti-Mem I medium (Gibco, cat.#31985-047), added to 0.5 mL of Opti-Mem containing 30 μl of PEI Max transfection reagent (40 kD, cat.#POL24765-1, Polysciences), and incubated at room temperature (RT) for 20 minutes. Then, the transfection mix was added to Expi293 cells (3×10 6While growing (cells / ml), it was added to a culture flask containing 80 ml of expression medium (GIBCO, cat#A14351-02) and incubated at 37 °C for 3 days under stirring. Then, the cells were collected, fixed with 4% formaldehyde for 20 minutes on ice, permeabilized with 0.5% saponin and 1% FBS in PBS for 20 minutes on ice, and stained with antibodies MPE33, MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, and MPE33_N34S_C38Y, MPF5_VH117D (MPF5), MPF5_VH117H, and the comparative antibody MPE8 (5 μg / ml in permeabilization buffer, 60 minutes at 4 °C). Binding was revealed by staining the cells with an AF647 goat anti-human IgG, Fcγ fragment-specific secondary antibody (Jackson, 109-606-098, 1 μg / ml for 30 minutes, on ice) and acquiring the cells with a flow cytometer.

[0248] The results are shown in Figure 8, with MPV_NL / 1 / 99_F0-TM in the upper row, HMPV_Yokohama / JPN (P8527) 2016 in the middle row, and mock transfection in the lower row. These data show that MPE33 and MPF5 and all their mutants bind equally well to the F proteins of both the hMPV strains of B1 (NL1 / 1 / 99) and B2 (Yokohama), while the B2 strain (bearing the D280N mutation) gives rise to virus escape mutants of the MPE8 antibody.

[0249] (Example 6: Competition studies of antibodies MPE33, MPF5, and MPE8) Binding / competition studies were performed to identify whether antibodies MPE33 and MPF5 bind to the same or different epitopes on the MPV F protein as the comparative antibody MPE8.

[0250] For this purpose, competition among antibodies MPE33, MPF5, and MPE8 was evaluated by biolayer interference using OCTET RED96 (ForteBio). Briefly, an APS sensor was loaded / coated with 5 μg / ml of MPV F protein in PBS for 10 minutes. Subsequently, the sensor was blocked with 1 mg / ml of BSA in PBS (blocking buffer) for 5 minutes. mAb association was performed by moving the sensor into two consecutive wells (7 minutes each) containing the first and second mAbs at 30 ug / ml each in blocking buffer. All steps were performed at 30°C under constant mixing at 1000 rpm.

[0251] The results are shown in Figure 9. The data demonstrate that MPF5 competes with MPE8, showing that both antibodies bind to the same or overlapping epitopes on the MPV F protein. However, MPE33 does not compete with either MPF5 or MPE8, showing that MPE33 binds to different epitopes on the MPV F protein compared to MPF5 and MPE8.

[0252] [Table 4] JPEG2023552846000006.jpg246169 JPEG2023552846000007.jpg210169 JPEG2023552846000008.jpg215169 [Brief explanation of the drawing]

[0253] [Figure 1] Figure 1 shows the binding characteristics of MPE33 and MPF5 antibodies to the hMPV F protein in the pre-fusion and post-fusion conformations compared to the reference antibody MPE8 for Example 1. [Figure 2]Figure 2 shows the neutralization of four different hMPV strains A1 / 6621 (MPV A1), A2 / VR8938 (MPV A2), B1 / VR4702 (MPV B1), and B2 / 3817 (MPV B2) with antibodies MPE33 and MPF5 compared to the reference antibody MPE8v3 in Example 2. [Figure 3] Figure 3 summarizes the EC50 values ​​required for neutralization of four different hMPV strains A1 / 6621 (MPV A1), A2 / VR8938 (MPV A2), B1 / VR4702 (MPV B1), and B2 / 3817 (MPV B2) with antibodies MPE33 and MPF5 compared to the reference antibody MPE8v3 for Example 2. [Figure 4] Figure 4 shows the binding affinity and EC50 values ​​of the antibodies MPF5_VH117D (MPF5), MPF5_VH117H, MPE33, and the comparative antibody MPE8v3 for the pre-fusion F protein of MPV in Example 3. [Figure 5] Figure 5 shows the VH and VL ("VK") sequences of the antibodies MPF5_VH117D (MPF5) and MPF5_VH117H. The squares indicate the position of substitution at amino acid position VH117. [Figure 6] Figure 6 shows the binding affinity and EC50 values ​​for the antibody MPE33, as well as its variants MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, and MPE33_N34S_C38Y, for the pre-fusion F protein of MPV in Example 4. [Figure 7] Figure 7 shows the VH and VL ("VK") sequences of the antibody MPE33. The squares indicate the positions of substitutions at amino acid positions N34, S36, and C38. [Figure 8]Figure 8 shows the binding of antibodies MPE33, MPE33_S36A, MPE33_N34Q, MPE33_N34S, MPE33_C38S, MPE33_C38A, MPE33_C38Y, MPE33_N34S_C38Y, MPF5_VH117D (MPF5), MPF5_VH117H, and the comparative antibody MPE8 to the cell-bound F antigen of the hMPV strains MPV_NL / 1 / 99_F0-TM (top panel) and HMPV_Yokohama / JPN(P8527)2016 (interrupted panel) in Example 5. The lower panel shows the simulated transfection (control). [Figure 9] Figure 9 shows the results of a competitive test of antibodies MPF5, MPE33, and MPE8 for binding to the MPV F protein in Example 6. As expected, the data show competition among the same antibodies (MPF5 vs. MPF5; MPE33 vs. MPE33; MPE8 vs. MPE8). Furthermore, the panel MPF5 vs. MPE8 and the panel MPE8 vs. MPF5 demonstrate competition between MPF5 and MPE8. However, no competition was observed between MPE33 and MPE8, or between MPE33 and MPF5.

Claims

1. An antibody or antigen-binding fragment thereof that binds to an F protein of a metapneumovirus (MPV), the antibody or antigen-binding fragment thereof (i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:7, respectively; or (iii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:18, respectively; or (iv) an antibody or antigen-binding fragment thereof comprising heavy chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 70% sequence identity to the amino acid sequences of SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:18, respectively. (a) the antibody or antigen-binding fragment thereof binds to a pre-fusion F protein of MPV, optionally, the antibody or antigen-binding fragment thereof specifically binds to the F protein of MPV subgroups A1, A2, B1, and B2; and / or (b) the antibody or antigen-binding fragment thereof neutralizes infection of MPV, optionally, the antibody or antigen-binding fragment thereof neutralizes infection of MPV subgroups A1, A2, B1, and B2.

3. the antibody or antigen-binding fragment thereof (i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:7, respectively; or (iii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity to the amino acid sequences of SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity to the amino acid sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:18, respectively; or (iv) the antibody or antigen-binding fragment thereof of claim 1 or 2, comprising heavy chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 80% sequence identity with the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 18, respectively.

4. the antibody or antigen-binding fragment thereof (i) heavy chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:7, respectively; or (ii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:7, respectively; or (iii) heavy chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:18, respectively; or (iv) the antibody or antigen-binding fragment thereof of any one of claims 1 to 3, comprising heavy chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity with the amino acid sequences of SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:14, respectively, and light chain CDR1, CDR2, and CDR3 sequences having at least 90% sequence identity with the amino acid sequences of SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:18, respectively.

5. the antibody or antigen-binding fragment thereof - the heavy chain CDR1 sequence according to SEQ ID NO:1; - the heavy chain CDR2 sequence according to SEQ ID NO:2; - a heavy chain CDR3 sequence having at least 90% sequence identity with the amino acid sequence of SEQ ID NO:3; - the light chain CDR1 sequence according to SEQ ID NO:4; - the light chain CDR2 sequence according to SEQ ID NO: 5 or 6; and - a light chain CDR3 sequence as set forth in SEQ ID NO:

7.

6. 6. The antibody or antigen-binding fragment thereof of claim 5, wherein the C-terminal Asp residue of SEQ ID NO: 3 has been substituted; optionally, replaced with another polar amino acid.

7. The antibody or antigen-binding fragment thereof of claim 5 or 6, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain CDR3 sequence as set forth in SEQ ID NO: 3 or 10.

8. The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO:1; - the heavy chain CDR2 sequence according to SEQ ID NO:2; - the heavy chain CDR3 sequence according to SEQ ID NO:3; - the light chain CDR1 sequence according to SEQ ID NO:4; - the light chain CDR2 sequence according to SEQ ID NO: 5 or 6; and - a light chain CDR3 sequence as set forth in SEQ ID NO: 7, or - the heavy chain CDR1 sequence according to SEQ ID NO:1; - the heavy chain CDR2 sequence according to SEQ ID NO:2; - the heavy chain CDR3 sequence according to SEQ ID NO: 10; - the light chain CDR1 sequence according to SEQ ID NO:4; - the light chain CDR2 sequence according to SEQ ID NO: 5 or 6; and - the light chain CDR3 sequence according to SEQ ID NO: 7, The antibody or antigen-binding fragment thereof according to any one of claims 1 to 7,

9. The antibody or antigen-binding fragment thereof: - a heavy chain CDR1 sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO: 12; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - a light chain CDR3 sequence as set forth in SEQ ID NO:

18.

10. one or more of the heavy chain variable region amino acid residues N34, S36, and C38 (corresponding to N6, S8, and C10 in SEQ ID NO: 12, respectively) are substituted; Optionally, - N34 (corresponding to N6 in SEQ ID NO: 12) is substituted with Gln (Q) or Ser (S); - S36 (corresponding to S8 in SEQ ID NO: 12) is substituted with Ala (A); and / or The antibody or antigen-binding fragment thereof according to claim 9, wherein -C38 (corresponding to C10 in SEQ ID NO: 12) is substituted with Ser (S), Ala (A) or Tyr (Y).

11. the heavy chain CDR1 sequence differs from SEQ ID NO: 12 by a single or exactly two amino acid substitutions from SEQ ID NO: 12; and / or the antibody or antigen-binding fragment thereof comprises a heavy chain CDR1 sequence set forth in any one of SEQ ID NOs: 12, 21, 23, 25, 27, 29, 31 and 33; An antibody or antigen-binding fragment thereof according to claim 9 or 10.

12. The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO: 12; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO: 21; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO: 23; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO: 25; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO:27; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO:29; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO: 31; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - comprising the light chain CDR3 sequence set forth in SEQ ID NO: 18, or The antibody or antigen-binding fragment thereof: - the heavy chain CDR1 sequence according to SEQ ID NO: 33; - the heavy chain CDR2 sequence according to SEQ ID NO: 13; - the heavy chain CDR3 sequence according to SEQ ID NO: 14; - the light chain CDR1 sequence according to SEQ ID NO: 15; - the light chain CDR2 sequence according to SEQ ID NO: 16 or 17; and - a light chain CDR3 sequence as set forth in SEQ ID NO: 18, An antibody or antigen-binding fragment thereof according to any one of claims 9 to 11.

13. the antibody or antigen-binding fragment thereof (i) a heavy chain variable region comprising an amino acid sequence having at least 70% identity to SEQ ID NO:8 and a light chain variable region comprising an amino acid sequence having at least 70% identity to SEQ ID NO:9; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 19 and a light chain variable region comprising an amino acid sequence having at least 70% identity to SEQ ID NO: 20; or the antibody or antigen-binding fragment thereof (i) a heavy chain variable region comprising an amino acid sequence having at least 75% identity to SEQ ID NO:8 and a light chain variable region comprising an amino acid sequence having at least 75% identity to SEQ ID NO:9; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 75% identity to SEQ ID NO: 19 and a light chain variable region comprising an amino acid sequence having at least 75% identity to SEQ ID NO: 20; or the antibody or antigen-binding fragment thereof (i) a heavy chain variable region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:8 and a light chain variable region comprising an amino acid sequence having at least 80% identity to SEQ ID NO:9; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 19 and a light chain variable region comprising an amino acid sequence having at least 80% identity to SEQ ID NO: 20; or the antibody or antigen-binding fragment thereof (i) a heavy chain variable region comprising an amino acid sequence having at least 85% identity to SEQ ID NO:8 and a light chain variable region comprising an amino acid sequence having at least 85% identity to SEQ ID NO:9; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 85% identity to SEQ ID NO: 19 and a light chain variable region comprising an amino acid sequence having at least 85% identity to SEQ ID NO: 20; or the antibody or antigen-binding fragment thereof (i) a heavy chain variable region comprising an amino acid sequence having at least 90% identity to SEQ ID NO:8 and a light chain variable region comprising an amino acid sequence having at least 90% identity to SEQ ID NO:9; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 19 and a light chain variable region comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 20; or the antibody or antigen-binding fragment thereof (i) a heavy chain variable region comprising an amino acid sequence having at least 95% identity to SEQ ID NO:8 and a light chain variable region comprising an amino acid sequence having at least 95% identity to SEQ ID NO:9; or (ii) a heavy chain variable region comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 19, and a light chain variable region comprising an amino acid sequence having at least 95% identity to SEQ ID NO:

20. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 12.

14. the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:8 and a light chain variable region set forth in SEQ ID NO:9; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:11 and a light chain variable region set forth in SEQ ID NO:9; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19 and a light chain variable region set forth in SEQ ID NO: 20; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:22 and a light chain variable region set forth in SEQ ID NO:20; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:24 and a light chain variable region set forth in SEQ ID NO:20; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:26 and a light chain variable region set forth in SEQ ID NO:20; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:28 and a light chain variable region set forth in SEQ ID NO:20; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:30 and a light chain variable region set forth in SEQ ID NO:20; or the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:32 and a light chain variable region set forth in SEQ ID NO:20; or The antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:34 and a light chain variable region set forth in SEQ ID NO:

20. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 13. (a) the antibody or antigen-binding fragment thereof is a human antibody, and / or (b) the antibody or antigen-binding fragment thereof is a monoclonal antibody, and / or (c) the antibody comprises an Fc portion, and / or (d) The antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, wherein the antibody is of the IgG type, and optionally the antibody is of the IgG1 type.

16. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, wherein the antibody or antigen-binding fragment thereof is Fab, Fab', F(ab')2, Fv or scFv.

17. A nucleic acid molecule comprising a polynucleotide encoding the antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, optionally (a) the polynucleotide encoding the antibody or antigen-binding fragment thereof is codon-optimized, and / or (b) a nucleic acid sequence according to any one of SEQ ID NOs: 38-55; or a sequence variant thereof having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity; Nucleic acid molecule.

18. A combination of a first and a second nucleic acid molecule, 17. The method of claim 1, wherein the first nucleic acid molecule comprises a polynucleotide encoding a heavy chain or an antigen-binding fragment thereof of an antibody according to any one of claims 1 to 16; and the second nucleic acid molecule comprises a polynucleotide encoding a corresponding light chain or an antigen-binding fragment thereof of the same antibody. Optionally, A combination of a first and a second nucleic acid molecule, wherein one or both of the polynucleotides encoding the heavy and / or light chains or antigen-binding fragments of said antibody are codon-optimized.

19. 19. A combination of nucleic acid molecules according to claim 18, comprising a nucleic acid sequence according to any one of SEQ ID NOs: 38 to 55; or a sequence variant thereof having at least 70%, at least 75%, at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

20. A combination of a first and a second nucleic acid molecule, (i) the first nucleic acid molecule comprises a polynucleotide encoding a heavy chain or an antigen-binding fragment thereof of an antibody, the polynucleotide comprising: (a) a nucleotide sequence set forth in SEQ ID NOs: 38, 39, and 40; or (b) a nucleotide sequence set forth in SEQ ID NOs: 47, 48, and 49; and (ii) a combination of a first and a second nucleic acid molecule, wherein the second nucleic acid molecule comprises a polynucleotide encoding a light chain or an antigen-binding fragment thereof of an antibody, the polynucleotide comprising: (c) a nucleotide sequence set forth in SEQ ID NOs: 41, 42 (or 43) and 44; or (d) a nucleotide sequence set forth in SEQ ID NOs: 50, 51 (or 52) and 53.

21. A vector comprising a nucleic acid molecule according to claim 17 or a combination of nucleic acid molecules according to any one of claims 18 to 20.

22. A combination of a first and a second vector, A combination of a first and a second vector, wherein the first vector comprises a first nucleic acid molecule according to any one of claims 18 to 20, and the second vector comprises a nucleic acid molecule corresponding to the second nucleic acid molecule according to any one of claims 18 to 20.

23. A cell expressing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, or comprising the vector according to claim 21 or a combination of vectors according to claim 22.

24. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, a nucleic acid according to claim 17, a combination of nucleic acids according to any one of claims 18 to 20, a vector according to claim 21, a combination of vectors according to claim 22, or a cell according to claim 23, and optionally a pharma- ceutically acceptable excipient, diluent or carrier.

25. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, a nucleic acid according to claim 17, a combination of nucleic acids according to any one of claims 18 to 20, a vector according to claim 21, a combination of vectors according to claim 22, a cell according to claim 23 or a pharmaceutical composition according to claim 24 for use as a medicament, or optionally in the prevention or treatment of MPV infection.

26. Use of an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 16 in the (in vitro) diagnosis of MPV infection.

27. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16 in a method for detecting an MPV antigen.

28. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16 for monitoring the quality of an anti-MPV vaccine by testing an antigen of said vaccine, optionally The use, wherein the conformation of the antigen or epitope thereof of said vaccine is examined.

29. 25. The pharmaceutical composition of claim 24 for use in the prevention, treatment or attenuation of MPV infection.

30. 17. A method for testing an anti-MPV vaccine, wherein the vaccine is contacted with an antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, and optionally the presence of an antibody / antigen complex is determined.